US 20110263566A1 ( 19 ) United States ( 12 ) Patent Applicati0n Publicati0n mm Pub. N0. : US 2011 / 0263566 A1 Matsu0 et al. ( 43 ) Pub. Date : 0ct. 27 , 2011 ( 54 ) 7 - HYDROXY - BENZOIMIDAZOLE - 4 - YL - ( 30 ) F0reign Applicati0n Pri0rity Data METHANONE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME Oct. 30 , 2008 ( US ) . 61 / 109801 Publicati0n Classiﬁcati0n ( 76 ) 111Vent0rs : Y0 Matsu0 , KanagaWa ( JP ) ; Yingfu ( 51 ) Int. Cl. Li , C1ift0n Park , NY ( US ) ; J eel A61K 31 / 4I84 ( 2006.01 ) Walker , Schenectady , NY ( US ) ; A61K 31 / 454 ( 200691 ) Feryan Ahmed , Latham , NY ( US ) ; C071 ) 403 / 12 ( 200691 ) Ryuji OhsaWa , KanagaWa ( JP ) ; A61P 35 / 00 ( 20O6 - 01 ) Sh0ji Hisada , KanagaWa ( JP ) ggg gggg gggggg C07D 235 / 06 ( 2006 : 01 ) ( 21 ) App1. N0. : 13 / 126 , 741 C07D 401 / I2 ( 2006.01 ) C07D 409 / 04 ( 2006.01 ) ( 22 ) PCT Fi1ed : Jul. 30 , 2009 ( 52 ) U. S. Cl. . 514 / 210.21 ; 546 / 199 ; 514 / 322 ; . 548 / 306.1 ; 514 / 394 ; 548 / 304.7 ; 544 / 370 ; 514 / 254.06 ; 548 / 304.4 ; 544 / 364 ; 514 / 253.09 ( 86 ) PCT N0. : PCT / US09 / 52228 ( 57 ) ABSTRACT. § 371 ( c ) ( 1 ) , 7 - Hydr0Xy - benZ0imidaz01e - 4 - y1 - metha110ne DeriVatiVes , ( 2 ) , ( 4 ) Date : Jul. 12 , 2011 Which are usefu1 f0r PBK inhibit0rs , are pr0Vided. US 2011 / 0263566 A1. 7 - HYDROXY - BENZOIMIDAZOLE - 4 - YLMETHANONE DERIVATIVES AND PBK INHIBITORS CONTAINING THE SAME. PRlORlTY. [ 0001 ] The present app1icati0n c1aims the beneﬁt 0f U. S. Pr0Visi0na1 App1icati0n N0. 61 / 109 , 801 , ﬁ1ed 0n Oct. 30 , 2008 , the entire c0ntents 0f Which are inc0rp0rated by reference herein. TECHNlCAL FlELD. [ 0002 ] The present inVenti0n re1ates t0 .3 c0mp0und f0r inhibiting PBK actiVity , a meth0d f0r the preparati0n there0f , and a pharmaceutica1 c0mp0siti0n c0ntaining the c0mp0und as an actiVe ingredient. BACKGROUND ART. [ 0003 ] PreVi0us studies reVea1ed that PDZ binding kinase ( PBK ) is a serine / thre0nine kinase re1ated t0 the dua1 speciﬁc mit0gen - actiVated pr0teir1 kinase kinase ( MAPKK ) fami1y ( AbeY , et a1. , J Bi01. Chem. 275 : 21525 - 21531 , 2000 , Gaudet S , et a1. , Pr0c Nat1Acad. Sci. 97 : 5167 - 5172 , 2000 and Matsum0t0 S , et a1. , Bi0chem Bi0phys Res C0mmun. 325 : 997 - 1004 , 2004 ) . PBK Was a1s0 indicated t0 be inV01Ved in mit0sis as sh0Wr1 by its signiﬁcant r01e in high1y pr01iferating spermat0cytes ( Gaudet S , et al. , Pr0c Nat1Acad. Sci. 97 : 5167 - 5172 , 2000 and Fujibuchi T , et a1. , DeV Gr0Wth Differ. 47 : 637 - 44 , 2005 ) . ln fact , abundant eXpressi0n 0f PBK Was 0bserVed in testis , Whi1e alm0st n0 PBK expressi0n Was detected in 0ther n0rma1 0rgans ( Park J H , et al. , Cancer Res. 66 : 9186 - 95 , 2006 ) . PBK regu1ates ce11 cyc1e pr0gressi0n. 111 acc0rdance With this , its signiﬁcant 0VereXpressi0n Was detected in c1inica1 breast cancer samp1es ( Park J H , et a1. , Cancer Res. 66 : 9186 - 95 , 2006 ) , Burkitts 1ymph0ma ( Si - m0ns - EVe1yn M , et al. , B100d Ce11s M01. Dis. 27 : 825 - 829 , 2001 ) and a Variety 0f hemat010 gic ma1ignancies ( Nandi A , et a1. , B100d Ce11s M01. Dis. 32 : 240 - 5 , 2004 ) . [ 0004 ] lmmun0hist0chemica1 ana1ysis 0f testis reVea1ed the eXpressi0n 0f PBK pr0tein ar0und the 0uter regi0n 0f seminifer0us tubu1es Where repeated mit0sis 0f sperm germ ce11s f0110Wed by mei0sis 0ccurs ( Fujibuchi T , et al. , DeV Gr0Wth Differ. 47 : 637 - 44 , 2005 ) . Especia11y , at pr0phase and metaphase , the subce11u1ar10ca1izati0n 0f PBK Was detected ar0und the c0ndensed chr0m0s0me in breast cancer ce11s ( Park J H , et a1. , Cancer Res. 66 : 9186 - 95 , 2006 ) . M0re0Ver the kn0ckd0Wr1 0f PBK expressi0r1 With gene speciﬁc siRNAs caused dysfuncti0n 0f cyt0kinesis and subsequent1y 1ed t0 ap0pt0sis 0f the cancer ce11s ( Park J H , et a1. , Cancer Res. 66 : 9186 - 95 , 2006 ) . These indicated the critica1 ﬁJncti0n 0f PBK at mit0sis , in testicu1ar and cancer ce11s. [ 0005 ] Taken t0gether , PBK - speciﬁc inhibit0rs can be used as a drug app1icab1e f0r a br0ad spectrum 0f cancers. PBK is an eXce11ent target f0r cancer therapy f0r the f0110Wing rea - s0ns : i ) a1m0st n0 eXpressi0n in n0rma1 0rgans ( eXcept f0r testis ) ; ii ) frequent 0VereXpressi0n in c1inica1 cancer samp1es ; iii ) a serine / thre0nine kinase re1ated t0 the essentia1 ﬁmction f0r ce11 mit0sis. [ 0006 ] The present inVent0rs haVe endeaV0red t0 deVe10p an effectiVe inhibit0r 0f PBK and haVe f0und that a 7 - hy - . Oct. 27 , 2011. dr0Xy - benz0imidaz01e - 4 - y1 - methan0ne deriVatiVe can se1ectiVe1y inhibit the actiVity 0f PBK. SUMMARY OF lNVENTlON. [ 0007 ] Acc0rding1y , it is an 0bject 0f the present inVenti0n t0 pr0Vide a PBK inhibit0r haVing high inhibit0ry actiVity against PBK. [ 0008 ] lt is an0ther 0bject 0f the present inVenti0n t0 pr0 - Vide a meth0d f0r preparing such inhibit0r. [ 0009 ] lt is a ﬁthher 0bject 0f the present inVenti0n t0 pr0Vide a pharmaceutica1 c0mp0siti0n inc1uding the c0m - p0und , a pharmaceutica11y acceptab1e sa1t , hydrate , so1Vate , 0r is0mer there0f. [ 0010 ] 1n acc0rdance With 0ne aspect 0f the present inVen - ti0n , there is pr0Vided a c0mp0und 0f f0rmu1a ( l ) , and a pharmaceutica11y acceptab1e sa1t , hydrate , s01Vate , 0r is0mer there0f : . O L—. ( CH2 ) —M N. \>7x E. OH. Wherein. [ 0011 ] X is pheny1 , thi0phen - 2 - y1 , furan - 2 - y1 , cyc10pr0 - py1 , cyc10penty1 , pheny1C1 - C6 a1ky1 , thi0phen - 2 - y1Cl - C6 a1ky1 , ﬁJran - 2 - y1C1 - C6 alky1 , cyc10pr0py1Cl - C6 a1ky1 , cyc10per1ty1Cl - C6 alky1 , 0r bicyc1e [ 2.2.1 ] heptar1 - 2 - y1 ; . the pheny1 , thi0phen - 2 - y1 , ﬁ1ran - 2 - y1 , cyc10pr0py1 , cyc10pen - ty1 , pheny1C1 - C6a1ky1 , thi0phen - 2 - y1Cl - C6 a1ky1 , ﬁ1ran - 2 - y1C 1 ' C6 a1ky1 , cyc10pr0py1C1 - C6 alky1 , 0r cyc10per1ty1Cl - C6 a1ky1 are 0pti0na11y substituted by 1 - 3 substituent ( s ) each independent1y se1ected fr0m gr0up A ; . L is —NH— 0r a sing1e b0nd ; . M is se1ected fr0m C3 - ClO cyc10a1ky1 0r 3 - 10 membered saturated heter0cyc1ic gr0up ; . the C3 ' C1o cyc10a1ky1 , and 3 - 8 membered saturated heter0 - cyc1ic gr0up are 0pti0na11y substituted by 1 - 3 substituent ( s ) each independent1y se1ected fr0m gr0up A ; . [ 0012 ] Wherein gr0up A 00nsists 0f hydr0Xy1 , 0x0 , nitr0 , cyan0 , amin0 , Cl - C6 a1ky1amin0 , C3 - ClO cyc10a1ky - 1amin0 , amide , ha10gen , su1fam0y1 , triﬁu010methy1 , p - t01uenesu1f0ny1amin0 , C1 - C6 a1ky1 , C3 - ClO cyc10a1ky1 , C1 ' C6 a1k0Xy , C1 ' C6 a1k0Xycarb0ny1 , C1 ' C6 a1ky1carb0ny1amin0 , Cl - C6 a1ky1su1f0ny1 , Cl - C6 a1ky1 - su1f0ny1amin0 , C1 ' C5 a1keny1 , C1 ' C5 a1kyny1 , ph0sph0 - ry1 , carb0ny1 , carb0Xy1 , and 3 - 8 membered saturated heter0cyc1ic gr0up ; and. a is an integer fr0m O - 5. DESCRlPTlON OF EMBODlMENTS Deﬁniti0n. [ 0013 ] ln this inVenti0n , “a1ky1” refers t0 a straight chain 0r a branched chain hydr0carb0n gr0up Which d0es n0t c0ntain any heter0 at0ms 0r unsaturated carb0n - carb0n b0nds. “C 1 ' . US 2011 / 0263566 A1. C6 a1ky1” refers t0 an a1ky1 gr0up Which has 1 - 6 carb0n at0m ( s ) . “C1 - C4 a1ky1” refers t0 an a1ky1 gr0up Which has 1 - 4 carb0n at0m ( s ) . [ 0014 ] EXamp1es 0f “C 1 - C6 a1ky1” inc1ude , but are n0t1imited t0 , methy1 , ethy1 , 1 - pr0py1 , 2 - pr0py1 , 2 - methy1 - 1 - pr0py1 , 2 - methy1 - 2 - pr0py1 ( tert - buty1 ( 1 , 1 - dimethy1 - ethy1 ) , 1 - buty1 , 2 - buty1 , 1 - penty1 , 2 - penty1 , 3 - penty1 , 2 - methy1 - 1 - buty1 , 3 - methy1 - 1 - buty1 , 2 - methy1 - 2 - buty1 , 3 - methy1 - 2 - buty1 , 2 , 2 - dimethy1 - 1 - pr0py1 , 1 - heXy1 , 2 - hexy1 , 3 - heXy1 , 2 - methy1 - 1 - penty1 , 3 - methy1 - 1 - penty1 , 4 - methy1 - 1 - penty1 , 2 - methy1 - 2 - penty1 , 3 - methy1 - 2 - penty1 , 4 - methy1 - 2 - penty1 , 2 - methy1 - 3 - penty1 , 3 - methy1 - 3 - penty1 , 2 , 3 - dimethy1 - 1 - buty1 , 3 , 3 - dimethy1 - 1 - buty1 , 2 , 2 - dimethy1 - 1 - buty1 , 2 - ethy1 - 1 - buty1 , 3 , 3 - dimethy1 - 2 - buty1 , and 2 , 3 - dimethy1 - 2 - buty1. [ 0015 ] 1n thjs inVenti0n , “pheny1Cl - C6 a1ky1 , thi0phen - 2 - y1Cl - C6 a1ky1 , furan - 2 - y1C1 - C6 a1ky1 , cyc10pr0py1Cl - C6 a1ky1 , 0r cyc10penty1Cl - C6 a1ky1” refers t0 the Cl - C6 a1ky1 b0und t0 a pheny1 , thi0phen - 2 - y1 , furan - 2 - y1 , cyc10pr0py1 0r cyc10penty1 gr0up. 1n 0ne emb0diment , pheny1C1 - C6 a1ky1 , thi0phen - 2 - y1Cl - C6 a1ky1 , ﬁJran - 2 - y1C1 - C6 a1ky1 , cyc10pr0 - py1C 1 ' C6 a1ky1 , 0r cyc10per1ty1Cl - C6 a1ky1 is 0pti0na11y substituted by 1 - 3 substituent ( s ) each independent1y se1ected fr0m the gr0up A menti0ned ab0Ve. Such substituti0n may 0ccur at either the pheny1 , thi0phen - 2 - y1 , ﬁJran - 2 - y1 , cyc10 - . pr0py1 , 0r cyc10penty1 m0iety 0r the Cl - C6 a1ky1 m0iety 0f. said gr0up , 0r may 0ccur at b0th m0ieties 0f said gr0up. [ 0016 ] Examp1es 0f “pheny1Cl - C6 a1ky1 , thi0phen - 2 - y1C 1 ' C6 a1ky1 , furan - 2 - y1Cl - C6 a1ky1 , cyc10pr0py1Cl - C6 a1ky1 , 0r cyc10penty1C 1 ' C6 a1ky1” inc1ude , but are n0t 1imited t0 , phe - ny1methy1 , pheny1ethy1 , pheny1 - 1 - pr0py1 , pheny1 - 2 - pr0py1 , pheny1 - n - buty1 , pheny1 - s - buty1 , pheny1 - t - buty1 , pheny1 - 2 - ethy1buty1 , thi0phen - 2 - y1methy1 , thi0phen - 2 - y1ethy1 , thi0phen - 2 - y1 - 1 - pr0py1 , thi0phen - 2 - y1 - 2 - pr0py1 , thi0phen - 2 - y1 - n - buty1 , thi0phen - 2 - y1 - s - buty1 , thi0phen - 2 - y1 - t - buty1 , thi0phen - 2 - y1 - 2 - ethy1buty1 , ﬁJran - 2 - y1methy1 , furan - 2 - y1 - ethy1 , furan - 2 - y1 - 1 - pr0py1 , furan - 2 - y1 - 2 - pr0py1 , furan - 2 - y1 - n - buty1 , furan - 2 - y1 - s - buty1 , furan - 2 - y1 - t - buty1 , furan - 2 - y1 - 2 - ethy1buty1 , cyc10pr0py1methy1 , cyc10pr0py1ethy1 , cyc10pr0py1 - 1 - pr0py1 , cyc10pr0py1 - 2 - pr0py1 , cyc10pr0py1 - n - buty1 , cyc10pr0py1 - s - buty1 , cyc10pr0py1 - t - buty1 , cyc10pr0py1 - 2 - ethy1buty1 , cyc10penty1methy1 , cyc10penty1ethy1 , cyc10 - penty1 - 1 - pr0py1 , cyc10penty1 - 2 - pr0py1 , cyc10penty1 - n - buty1 , cyc10penty1 - s - buty1 , cyc10penty1 - t - buty1 and cyc10penty1 - 2 - ethy1buty1. [ 0017 ] 1n this inVenti0n , “a1ker1y1” refers t0 a straight chain 0r a branched chain hydr0carb0n gr0up Whjch c0ntains 0ne 0r m0re than 0ne unsaturated carb0n - carb0n b0nd ( s ) and d0es n0t c0ntain any heter0 at0ms. “C2 - C6 a1keny1” refers t0 an a1keny1 gr0up Which has 2 - 6 carb0n at0ms. [ 0018 ] EXamp1es 0f “C2 - C6 a1keny1” inc1ude , but are n0t 1imited t0 , Viny1 ( etheny1 ) , 1 - pr0peny1 , 2 - pr0peny1 , 3 - pr0pe - ny1 , 2 - methy1 - pr0p - 1 - en - 1 - y1 ( 2 - methy1 - 1 - pr0peny1 ) , 2 - methy1 - pr0p - 1 - en - 3 - y1 ( 2 - methy1 - 2 - pr0peny1 ) , but - 1 - en - 1 - y1 , but - 1 - en - 2 - y1 , but - 1 - en - 3 - y1 , but - 2 - en - 1 - y1 , but - 2 - en - 2 - y1 , pent - 1 - en - 1 - y1 , pent - 1 - en - 2 - y1 , pent - 1 - en - 3 - y1 , pent - 1 - en - 4 - y1 , pent - 1 - en - 5 - y1 , pent - 2 - en - 1 - y1 , pent - 2 - en - 2 - y1 , pent - 2 - en - 3 - y1 ( 1 - ethy1 - 1 - pr0peny1 ) , pent - 2 - en - 4 - y1 , pent - 2 - en - 5 - y1 , 2 - methy1 - but - 1 - en - 1 - y1 , 2 - methy1 - but - 1 - en - 2 - y1 , 2 - methy1 - but - 1 - en - 3 - y1 , 2 - methy1 - but - 1 - en - 4 - y1 , 2 - methy1 - but - 2 - en - 1 - y1 , 2 - methy1 - but - 2 - en - 3 - y1 , 2 - methy1 - but - 2 - en - 4 - y1 , 3 - methy1 - but - 1 - en - 1 - y1 , 3 - methy1 - but - 1 - en - 2 - y1 , 3 - methy1 - but - 1 - en - 3 - y1 , 3 - methy1 - but - 1 - en - 4 - y1 , 2 , 2 - dimethy1 - pr0p - 1 - en - 1 - y1 , 2 , 2 - dimethy1 - pr0p - 1 - en - 2 - y1 , heX - 1 - en - 1 - y1 , hex - 1 - en - 2 - y1 , heX - 1 - en - 3 - y1 , heX - 1 - en - 4 - y1 , heX - 1 - en - 5 - y1 , hex - 1 - en - 6 - . Oct. 27 , 2011. y1 , heX - 2 - en - 1 - y1 , hex - 2 - en - 2 - y1 , hex - 2 - en - 3 - y1 , hex - 2 - en - 4 - y1 , heX - 2 - en - 5 - y1 , heX - 2 - en - 6 - y1 , heX - 3 - en - 1 - y1 , heX - 3 - en - 2 - y1 , heX - 3 - en - 3 - y1 , 2 - methy1 - pent - 1 - en - 1 - y1 , 2 - methy1 - pent - 1 - en - 3 - y1 , 2 - methy1 - pent - 1 - en - 4 - y1 , 2 - methy1 - pent - 1 - en - 5 - y1 , 2 - methy1 - pent - 2 - en - 1 - y1 , 2 - methy1 - pent - 2 - en - 3 - y1 , 2 - methy1 - pent - 2 - en - 4 - y1 , 2 - methy1 - pent - 2 - en - 5 - y1 , 3 - methy1 - pent - 1 - en - 1 - y1 , 3 - methy1 - pent - 1 - en - 2 - y1 , 3 - methy1 - pent - 1 - en - 3 - y1 , 3 - methy1 - pent - 1 - en - 4 - y1 , 3 - methy1 - pent - 1 - en - 5 - y1 , 3 - methy1 - pent - 2 - en - 1 - y1 , 3 - methy1 - pent - 2 - en - 2 - y1 , 3 - methy1 - pent - 2 - en - 4 - y1 , 3 - methy1 - pent - 2 - en - 5 - y1 , 4 - methy1 - pent - 1 - en - 1 - y1 , 4 - methy1 - pent - 1 - en - 2 - y1 , 4 - methy1 - pent - 1 - en - 3 - y1 , 4 - methy1 - pent - 1 - en - 4 - y1 , 4 - methy1 - pent - 1 - en - 5 - y1 , 4 - methy1 - pent - 2 - en - 1 - y1 , 4 - methy1 - pent - 2 - en - 2 - y1 , 4 - methy1 - pent - 2 - en - 3 - y1 , 4 - methy1 - pent - 2 - en - 4 - y1 , 4 - methy1 - pent - 2 - en - 5 - y1 , 2 , 3 - dimethy1 - but - 1 - en - 1 - y1 , 2 , 3 - dimethy1 - but - 1 - en - 3 - y1 , 2 , 3 - dimethy1 - but - 1 - en - 4 - y1 , 2 , 3 - dimethy1 - but - 2 - en - 1 - y1 , 3 , 3 - dimethy1 - but - 1 - en - 1 - y1 , 3 , 3 - dimethy1 - but - 1 - en - 2 - y1 , 3 , 3 - dimethy1 - but - 1 - en - 4 - y1 , 2 - ethy1 - but - 1 - en - 1 - y1 , 2 - ethy1 - but - 1 - en - 3 - y1 , 2 - ethy1 - but - 1 - en - 4 - y1 , 3 - ethy1 - but - 1 - en - 1 - y1 , 3 - ethy1 - but - 1 - en - 2 - y1 , 3 - ethy1 - but - 1 - en - 3 - y1 , 3 - ethy1 - but - 1 - en - 4 - y1 , 2 - ethy1 - but - 2 - en - 1 - y1 , 2 - ethy1 - but - 2 - en - 3 - y1 and 2 - ethy1 - but - 2 - en - 4 - y1. [ 0019 ] 1n this inVenti0n , “a1kyny1” refers t0 3 straight chain 0r a branched chain hydr0carb0n gr0up Which c0ntains at 1east 0ne trip1e carb0n - carb0n b0nd and d0es n0t c0ntain any heter0 at0ms. “C2 - C6 a1kyny1” refers t0 an a1kyny1 gr0up Which has 2 - 6 carb0n at0ms. [ 0020 ] EXamp1es 0f “C2 - C6 a1kyny1” inc1ude , but are n0t 1imited t0 , ethjny1 , 1 - pr0piny1 , 2 - pr0piny1 , 3 - pr0piny1 , 2 - methy1 - pr0p - 1 - in - 1 - y1 , 2 - methy1 - pr0p - 1 - in - 3 - y1 , but - 1 - in - 1 - y1 , but - 1 - in - 2 - y1 , but - 1 - in - 3 - y1 , but - 2 - in - 1 - y1 , but - 2 - in - 2 - y1 , pent - 1 - in - 1 - y1 , pent - 1 - in - 2 - y1 , pent - 1 - in - 3 - y1 , pent - 1 - ir1 - 4 - y1 , pent - 1 - in - 5 - y1 , pent - 2 - in - 1 - y1 , pent - 2 - in - 2 - y1 , pent - 2 - in - 3 - y1 , pent - 2 - in - 4 - y1 , pent - 2 - in - 5 - y1 , 2 - methy1 - but - 1 - in - 1 - y1 , 2 - methy1 - but - 1 - in - 2 - y1 , 2 - methy1 - but - 1 - in - 3 - y1 , 2 - methy1 - but - 1 - in - 4 - y1 , 2 - methy1 - but - 2 - in - 1 - y1 , 2 - methy1 - but - 2 - in - 3 - y1 , 2 - methy1 - but - 2 - in - 4 - y1 , 3 - methy1 - but - 1 - in - 1 - y1 , 3 - methy1 - but - 1 - in - 2 - y1 , 3 - methy1 - but - 1 - in - 3 - y1 , 3 - methy1 - but - 1 - in - 4 - y1 , 2 , 2 - dimethy1 - pr0p - 1 - in - 1 - y1 , 2 , 2 - dimethy1 - pr0p - 1 - in - 2 - y1 , heX - 1 - in - 1 - y1 , hex - 1 - in - 2 - y1 , heX - 1 - in - 3 - y1 , heX - 1 - in - 4 - y1 , hex - 1 - in - 5 - y1 , heX - 1 - in - 6 - y1 , heX - 2 - in - 1 - y1 , heX - 2 - in - 2 - y1 , hex - 2 - in - 3 - y1 , hex - 2 - in - 4 - y1 , heX - 2 - in - 5 - y1 , heX - 2 - in - 6 - y1 , heX - 3 - in - 1 - y1 , heX - 3 - in - 2 - y1 , heX - 3 - in - 3 - y1 , 2 - methy1 - pent - 1 - in - 1 - y1 , 2 - methy1 - pent - 1 - in - 3 - y1 , 2 - methy1 - pent - 1 - in - 4 - y1 , 2 - methy1 - pent - 1 - in - 5 - y1 , 2 - methy1 - pent - 2 - in - 1 - y1 , 2 - methy1 - pent - 2 - in - 3 - y1 , 2 - methy1 - pent - 2 - in - 4 - y1 , 2 - methy1 - pent - 2 - in - 5 - y1 , 3 - methy1 - per1t - 1 - in - 1 - y1 , 3 - methy1 - pent - 1 - ir1 - 2 - y1 , 3 - methy1 - pent - 1 - in - 3 - y1 , 3 - methy1 - pent - 1 - in - 4 - y1 , 3 - methy1 - pent - 1 - in - 5 - y1 , 3 - methy1 - pent - 2 - in - 1 - y1 , 3 - methy1 - pent - 2 - in - 2 - y1 , 3 - methy1 - pent - 2 - in - 4 - y1 , 3 - methy1 - pent - 2 - in - 5 - y1 , 4 - methy1 - pent - 1 - in - 1 - y1 , 4 - methy1 - pent - 1 - in - 2 - y1 , 4 - methy1 - pent - 1 - in - 3 - y1 , 4 - methy1 - per1t - 1 - in - 4 - y1 , 4 - methy1 - pent - 1 - ir1 - 5 - y1 , 4 - methy1 - pent - 2 - in - 1 - y1 , 4 - methy1 - pent - 2 - in - 2 - y1 , 4 - methy1 - pent - 2 - in - 3 - y1 , 4 - methy1 - pent - 2 - in - 4 - y1 , 4 - methy1 - pent - 2 - in - 5 - y1 , 2 , 3 - dimethy1 - but - 1 - in - 1 - y1 , 2 , 3 - dimethy1 - but - 1 - in - 3 - y1 , 2 , 3 - dimethy1 - but - 1 - in - 4 - y1 , 2 , 3 - dimethy1 - but - 2 - in - 1 - y1 , 3 , 3 - dimethy1 - but - 1 - in - 1 - y1 , 3 , 3 - dimethy1 - but - 1 - in - 2 - y1 , 3 , 3 - dimethy1 - but - 1 - in - 4 - y1 , 2 - ethy1 - but - 1 - in - 1 - y1 , 2 - ethy1 - but - 1 - in - 3 - y1 , 2 - ethy1 - but - 1 - in - 4 - y1 , 3 - ethy1 - but - 1 - in - 1 - y1 , 3 - ethy1 - but - 1 - in - 2 - y1 , 3 - ethy1 - but - 1 - in - 3 - y1 , 3 - ethy1 - but - 1 - in - 4 - y1 , 2 - ethy1 - but - 2 - in - 1 - y1 , 2 - ethy1 - but - 2 - in - 3 - y1 and 2 - ethy1 - but - 2 - in - 4 - y1. [ 0021 ] 1n the present inVenti0n , “a1k0Xy” refers t0 a gr0up represented by —OR , Wherein R is a1ky1. US 2011 / 0263566 A1. [ 0022 ] “C 1 - C6 a1k0Xy” refers t0 an a1k0xy gr0up Which has 1 - 6 carb0n at0m ( s ) . “C1 - C4 a1k0Xy” refers t0 an a1k0Xy gr0up Which has 1 - 4 carb0n at0m ( s ) . [ 0023 ] EXamp1es 0f “Cl ' C6 a1k0Xy” inc1ude , but are n0t 11mited t0 , meth0Xy , eth0Xy , 1 - pr0py10Xy , 2 - pr0py10Xy , 2 - methy1 - 1 - pr0py10xy , 2 - methy1 - 2 - pr0py10xy , and 1 - buty10Xy , and 2 - buty10xy. [ 0024 ] 1n this inVenti0n , “C1 - C6 a1ky1carb0ny1” refers t0 R—C : O— Wherein R is C1 - C6a1ky1. “C 1 - C4 a1ky1carb0ny1” refers t0 R—C : O— Wherein R is C l - C4a1ky1. [ 0025 ] Examp1es 0f “C 1 ' C6 a1ky1carb0ny1” inc1ude , but are n0t 1imited t0 , methy1carb0ny1 ( acety1 ) , ethy1carb0ny1 , pr0 - py1carb0ny1 , is0 - pr0py1carb0ny1 , n - buty1carb0ny1 , s - buty1 - carb0ny1 , t - buty1carb0ny1 , and 2 - ethy1buty1carb0ny1. [ 0026 ] 1n thjs inVenti0n , “C 1 - C6 a1k0Xycarb0ny1” refers t0 a carb0ny1 gr0up b0und t0 the C1 ' C6 a1k0Xy. “Cl - C4 a1k0Xycarb0ny1” refers t0 a carb0ny1 gr0up b0und t0 the C1 - C4 a1k0Xy. [ 0027 ] EXamp1es 0f “C1 - C6 a1k0Xycarb0ny1” inc1ude , but are n0t 1imited t0 , meth0xycarb0ny1 , eth0Xycarb0ny1 , pr0 - p0xycarb0ny1 , and t - but0Xycarb0ny1. [ 0028 ] 1n the present inVenti0n , “cyc10a1ky1” refers t0 a saturated carb0n ring system. “C3 - C10 cyc10a1ky1” refers t0 3 - 10 membered cyc10a1ky1. [ 0029 ] EXamp1es 0f “C3 - C10 cyc10a1ky1” inc1ude , but are n0t 11mited t0 , cyc10pr0py1 , cyc10buty1 , cyc10penty1 , cyc10 - hexy1 , cyc10heptany1 , cyc100ctany1 , and adamanty1. F0r eXamp1e , 3 - 8 membered cyc10a1ky1 is a1s0 inc1uded in “C3 - C 10 cyc10a1ky1”. [ 0030 ] 1n this i11Ve11ti011 , “a111i110” refers t0 a gr0up represented by 7NH2 Wh0se hydr0gens may each be 0pti0na11y substituted by a substituent. [ 0031 ] 1n the present inVenti0n , “C 1 ' C6 a1ky1a111i110” refers t0 a11 a111i110 gr0up b0u11d t0 the C 1 ' C6 a1ky1. [ 0032 ] EXarnp1es 0f “C1 - C6 a1ky1amin0” inc1ude , but are n0t 1imited t0 , methy1a111i110 , ethy1amin0 , pr0py1amin0 , is0 - pr0py1amin0 , 11 - buty1amin0 , s - buty1amin0 , t - buty1ami110 , and 2 - ethy1buty1amin0. [ 0033 ] 1n the present inVenti0n , “Cl - C6 a1ky1carb011y - 1amin0” refers t0 R—C : O—NH— Wherein R is Cl - C6 a1ky1. “Cl - C4 a1ky1carb0ny1amin0” refers t0 R—C : O— NH— Wherein R is C l - C4 a1ky1. [ 0034 ] EXamp1es 0f “Cl - C6 a1ky1carb0ny1amin0” inc1ude , but are n0t 1imited t0 , methy1carb0ny1amin0 ( acety1 amin0 ) , ethy1carb0ny1amin0 , 1 - pr0py1carb0ny1amin0 , 2 - pr0py1car - b0ny1a111in0 , n - buty1carb0ny1amin0 , s - buty1carb0ny1amin0 , t - buty1carb0ny1amin0 , and 2 - ethy1buty1carb0ny1ami110. [ 0035 ] 1n the present inVenti0n , “C3 - C10 cyc10a1ky1amin0” refers t0 R—NH— Wherein R is C3 - C lOcyc10a11<y1. [ 0036 ] EXamp1es 0f “C3 - ClO cyc10a1ky1 amin0” inc1ude , but are n0t 11mited t0 , cyc10pr0py1a111in0 , cyc10buty1amin0 , cyc10penty1ami110 , cyc10heXy1ami110 , cyc10heptany1amin0 , and cyc100ctany1 amin0. [ 0037 ] 1n this inVenti0n , “su1f0ny1” is a gr0up represented by 7SO27. [ 0038 ] 1n this inVenti0n , “Cl - C6 a1ky1su1f0ny1” refers t0 R—SO2— Wherein R is the Cl - C6 a1ky1. “Cl - C4 a1ky1su1f0 - ny1” refers t0 R7SO27 Wherein R is C1 - C4 a1ky1. [ 0039 ] EXamp1es 0f “C 1 - C6 a1ky1su1f0ny1” inc1ude , but are n0t 1imited t0 , methy1su1f0ny1 , ethy1su1f0ny1 , pr0py1su1f0ny1 , is0pr0py1su1f0ny1 , n - buty1su1f0ny1 , s - buty1su1f0ny1 , t - buty1 - su1f0ny1 , and 2 - ethy1buty1su1f0ny1. [ 0040 ] 1n the present inVenti0n , “C1 - C6a1ky1su1f0ny1amin0” refers t0 R—SO2—NH— Wherein R. Oct. 27 , 2011. is “Cl - C6 a1ky1”. “C1 - C4 a1ky1su1f0ny1amin0” refers t0 R7SO27NH7 Wherein R is R7SO27NH7 Wherein R is “C 1 - C4 a1ky1”. [ 0041 ] EXamp1es 0f “Cl - C6 a1ky1su1f0ny1amin0” inc1ude , but are n0t 1imited t0 , methy1su1f0ny1amin0 , ethy1su1f0ny - 1amin0 , pr0py1su1f0ny1amin0 , is0pr0py1su1f0ny1amin0 , n - buty1su1f0ny1amin0 , s - buty1su1f0ny1amin0 , t - buty1su1f0ny - 1amin0 , and 2 - ethy1buty1su1f0ny1amin0. [ 0042 ] 1n the present inVenti0n , “a saturated heter0cyc1ic gr0up” refers t0 a saturated heter0cyc1ic gr0up haVing 0ne 01 m0re than 0ne heter0 at0m ( s ) in the ring system. “3 - 8 membered saturated heter0cyc1ic gr0up” refers t0 a saturated het - er0cyc1ic gr0up Wh0se ring c0nsists 0f 3 - 8 at0ms. [ 0043 ] EXamp1es 0f “3 - 8 membered saturated heter0cyc1ic gr0up” inc1ude , but are n0t 1imited t0 , aziridiny1 , azetidiny1 , pyrr01idiny1 , imidaZ01idiny1 , piperaziny1 , piperidiny1 , aZepa - ny1 , and m0rph01iny1. [ 0044 ] A sa1t is deﬁned as the pr0duct f0rmed fr0m the neutra1isati0n reacti0n 0f acids and bases. Sa1ts are ionic c0mp0unds c0mp0sed 0f cati0ns ( p0sitiVe1y charged ions ) and ani0ns ( negatiVe i0ns ) SO that the pr0duct is e1ectrica11y neutra1. These c0mp0nent i0ns can be in0rganic as We11 as 0rganic. [ 0045 ] Hydrate is a term used in in0rganic chemistry and 0rganic chemistry t0 indicate that a substance c0ntains Water. SO1Vate refers t0 a m01ecu1e in a s01uti0n c0mp1eXed by so1 - Vent m01ecu1es. [ 0046 ] 1s0mers are c0mp0unds With the same m01ecu1ar f0rmu1a but different structura1 f0rmu1ae. M0re speciﬁca11y , is0mer inc1udes ge0metric is0mer , 0ptica1 is0mer , stere0is0 - mer , taut0mer 0f the c0mp0u11d , and mixtures there0f. [ 0047 ] The present inVenti0n pr0Vides a 00mp0und represented by f0rmu1a ( 1 ) : . ( 1 ) . 0 L— ( CH2 ) , , —M. N. \>_x. N H OH. Wherein. [ 0048 ] X is pheny1 , thi0phen - 2 - y1 , furan - 2 - y1 , cyc10pr0 - py1 , cyc10penty1 , pheny1C1 - C6a1ky1 , thi0phen - 2 - y1C1 - C6 a1ky1 , furan - 2 - y1C1 - C6 a1ky1 , cyc10pr0py1Cl - C6 a1ky1 , cyc10penty1Cl - C6 a1ky1 , 0r bicyc1e [ 2.2.1 ] heptan - 2 - y1 ; . the pheny1 , thi0phen - 2 - y1 , ﬁ1ran - 2 - y1 , cyc10pr0py1 , cyc10pen - ty1 , pheny1Cl - C6a1ky1 , thi0phen - 2 - y1Cl - C6a1ky1 , ﬁ1ran - 2 - y1Cl - C6a1ky1 , cyc10pr0py1C1 - C6 a1ky1 , 0r cyc10pe11ty1Cl - C6 a1ky1 are 0pti0na11y substituted by 1 - 3 substituent ( s ) each independent1y se1ected fr0m gr0up A ; . [ 0049 ] L is 7NH7 0r sing1e b0nd ; . [ 0050 ] M is se1ected C3 - C 10 cyc10a11<y1 0r 3 - 8 membered saturated heter0cyc1ic gr0up ; . the C3 - C10 cyc10a1ky1 , and 3 - 8 membered saturated heter0 - cyc1ic gr0up are 0pti0na11y substituted by 1 - 3 substituent ( s ) each independent1y se1ected fr0m gr0up A ; . [ 0051 ] Wherein gr0up A c0nsists 0f hydr0Xy1 , 0x0 , nitr0 , cyan0 , amin0 , Cl - C6 a1ky1amin0 , C3 - ClO cyc10a1ky - 1amin0 , amide , ha10gen , su1fam0y1 , triﬁu010methy1 , p - t01uenesu1f0ny1amin0 , C1 - C6 a1ky1 , C3 - ClO. US 2011 / 0263566 A1 Oct. 27 , 2011. cyc10a1ky1 , Cl - C6a1k0Xy , Cl - C6a1k0Xycarb0ny1 , Cl - C6 [ 0052 ] Preferred c0mp0u11ds inc1ude th0se se1ected fr0m a1ky1carb0ny1amin0 , C1 ' C6 a1ky1su1f0ny1 , C1 ' C6 a1ky1 - the gr0up c0nsisting 0f : EXamp1e N0s. 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , su1f0ny1amin0 , C1 - C6a1keny1 , C1 - C6a1kyny1 , ph0sph0 - 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , . ry1 , carb0ny1 , carb0Xy1 , and 3 - 8 membered saturated 434445.46 11148 49 50 515_2 53545556 57 5.859 and 60 11sted 1n Tab1e 1 be10W , and the phar111aceut1ca11y. . heter0cyc1ic group ; and acceptab1e sa1ts , pr0drugs , hydrates and s01Vates 0f the f0r - a is an integer fr0m 0 - 5. g0ing c0mp0unds. TABLE 1 Examp1e N0. Structure C0mp0und. . 5 2 - Cyc10pr0py1 - 4 - hydr0xy - N - ( piperidin - 4 - y1methy1 ) - 1H - ﬁH benz0 [ d ] imidaz01e - 7 - carb0Xamide H O N N N H. OH 6 2 - Cyc10pr0py1—4 - hydr0xy - N - ( piperidin - 3 - y1 - methy1 ) - 1H - benz0 [ d ] imidaz01e - 7 - carb0Xamide O E\ / O\IH. N H 7 2 - Cyc10pr0py1 - 4 - hydr0xy - N - ( piperidin - 2 - y1methy1 ) - 1H - ﬁ benz0 [ d ] imidaz01e - 7 - carb0Xamide H O N N H N N H. 8 / CH3 2 - cycl0pr0py1 - 4 - hydr0xy - N - ( 1 - methy1piperidin - 3 - y1 ) - 1H - Q benz0 [ d ] imidaz01e - 7 - carb0Xamide. OH. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 5 TABLE 1 - c0ntinued Examp1e N0. Structure C0mp0und 9 ( S ) - 2 - cyc10pr0py1 - 4 - hydr0Xy - N - ( pip eridin - 3 - y1 ) - 1H - NH benz0 [ d ] imidaz01e - 7 - carb0xam1de O NH. N 1H. OH 10 H N O NH N H N H OH 11 NH O NH N N H OH 12 QH O NH. N 1M. OH. 2 - cyc10pr0py1 - 4 - hydr0xy - N - ( piperidin - 4 - y1 ) - 1H - benz0 [ d ] imidaz01e - 7 - carb0xam1de. 2 - cycl0pr0py1 - 4 - hydr0xy - N - ( piperidin - 3 - y1 ) - 1H - benz0 [ d ] imidaz01e - 7 - carb0Xam1de. 2 - cyc10pr0py1 - 4 - hydr0xy - N - ( pyrr01idin - 3 - y1 ) - 1H - benz0 [ d ] imidaz01e - 7 - carb0Xam1de. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 6 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0u11d 13 ( quH N - ( azetidin - 3 - y1methy1 ) - 2 - cyc10pr0py1 - 4 - hydr0Xy - 1H - benz0 [ d ] imidaz01e - 7 - carb0Xamide. O NH. mZZ / Z. OH. 14 2 - cyc10penty1 - 4 - hydr0Xy - N - ( piperidin - 2 - y1methy1 ) - 1H - ﬁ benz0 [ d ] imidaz01e - 7 - carb0Xam1de H O N N H. OH. 15 2 - Cyc10penty1 - 4 - hydr0Xy - N - ( piperidin - 3 - y1methy1 ) - 1H - benz0 [ d ] imidaz01e - 7 - carb0Xamide O NVON H. OH. 16 ( S ) - 2 - Cyc10penty1 - 4 - hydr0xy - N - ( piperidin - 3 - y1 ) - 1H - NH benz0 [ d ] imidaz01e - 7 - carb0Xam1de. O Q % mz / ; 21. OH. US 2011 / 0263566 A1. TABLE 1 - c0ntinued. . EXamp1e N0. Structure C0mp0und. . 17 ( S ) - 4 - Hydr0xy - 2 - pheny1 - N - ( pip eridin - 3 - y1 ) - 1H - . NH benz0 [ d ] imidaz01e - 7 - carb0Xamide. C. O Q E E21 / Z. OH. 18 4 - Hydr0Xy - 2 - pheny1 - N - ( pip eridin - 2 - y1methy1 ) - 1 H - ﬁ benz0 [ d ] imidaz01e - 7 - carb0xamide N. O : zm mz / Z 6 m. 19 4 - hydr0Xy - 2 - phenyl - N - ( pip eridin - 3 - ylmethy1 ) - 1 H - benz0 [ d ] imidaz01e - 7 - carb0Xamide H\ / O O N NH. 20 7 - Hydr0Xy - N - ( 4 - hydr0Xycyc10hexy1 ) - 2 - ( thi0phen - 2 - yl ) - . 1H - benz0 [ d ] imidaz01e - 4 - carb0xamide. Oct. 27 , 2011. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 8 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0u11d 21 ( 7 - hydr0xy - 2 - [ thi0phen - 2 - y1 ] - 1 H - benz0 [ d ] imidaz01 - 4 - y1 ) p NH ( piperazin - 1 - y1 ) methan0ne O N\ ) N S W N \ H OH 35 7 - Hydr0Xy - N - ( pip eridin - 3 - y1 ) - 2 - ( thi0phen - 2 - y1 ) - 1 H - NH benzcn [ d ] imidaz01e - 4 - carb0Xamide O NH N S W N \ H OH 3 6 H 7 - Hydr0Xy - N - [ 2 - ( piperazin - 1 - y1 ) ethy1 ] - 2 - ( thi0phen - 2 - y1 ) - ENj 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide N H\ ) O N N S W N H OH 37 ( R ) - 7 - Hydr0xy - N - ( piperidin - 3 - y1 ) - 2 - ( thi0phe11 - 2 - y1 ) - 1H - OH benz0 [ d ] imidaz01e - 4 - carb0Xamide 0 NH. OH. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 9 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0u11d 38 ( S ) - 7 - Hydr0xy - N - ( piperidin - 3 - y1 ) - 2 - ( thi0phen - 2 - y1 ) - 1H - . NH benz0 [ d ] imidaz01e - 4 - carb0Xamide. OH. 39 7 - Hydr0Xy - N - ( piperidin - 3 - ylmethy1 ) - 2 - ( thi0phen - 2 - yl ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0xamide O N\ / O\1H. OH 40 H 7 - Hydr0Xy - N - ( piperidin - 4 - y1 ) - 2 - ( thi0phen - 2 - y1 ) - 1H - N benz0 [ d ] imidaz01e - 4 - carb0Xamide O NH N S W N \ H OH 41 / CH3 7 - Hydr0xy - N - ( 1 - methy1piperidin - 3 - y1 ) - 2 - ( thi0phen - 2 - y1 ) - N 1H - benz0 [ d ] imidaz01e - 4 - carb0xamide O NH. OH. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 1 0 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0und 42 7 - Hydr0Xy - N - ( piperidin - 4 - y1methy1 ) - 2 - ( thi0phen - 2 - y1 ) - NH 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide. OH. 43 NH N - ( Azetidin - 3 - y1methy1 ) - 7 - hydr0Xy - 2 - ( thi0phen - 2 - y1 ) - 1H - O E\ / C / benz0 [ d ] imidaz01e - 4 - carb0Xamide. 44 NH 7 - Hydr0Xy - N - ( pyrr0lidin - 3 - y1 ) - 2 - ( thi0phen - 2 - yl ) - 1H - Q benz0 [ d ] imidaz01e - 4 - carb0xamide. OH. 45 7 - Hydr0Xy - N - ( piperidin - 2 - y1methy1 ) - 2 - ( thi0phen - 2 - y1 ) w 1H - benz0 [ d ] imidaz01e - 4 - carb0xamide H O N. OH. 46 7 - Hydr0Xy - N - ( pyrr01idin - 3 - y1methy1 ) - 2 - ( thi0phen - 2 - y1 ) - 1 H H\ / CNH benz0 [ d ] imidaz01e - 4 - carb0xamide O N. OH. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 1 1 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0u11d 47 NH2 N - ( 4 - Amin0cyc10heXy1 ) - 7 - hydr0Xy - 2 - ( thi0phen - 2 - y1 ) - 1H - . benz0 [ d ] imidaz01e - 4 - carb0xamide. OH. 48 2 - ( Bicyc10 [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydr0xy - N - ( piperidin - 3 - y1methy1 ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide O N\ / O\1H. OH. 49 2 - ( Bicyc10 [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydr0xy - N - ( piperidin - 3 - NH y1 ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide. 50 ) - - tert Buty13 - ( 2 - ( 5 - br0m0thi0phen - 2 - - - y1 ) - - 7 - hydr0Xy - 1H - . Ni OX bSenz0 [ d ] imidaz01e - 4 - carb0Xamid0 ) piperidine - 1 - carb0Xy1ate. US 2011 / 0263566 A1. . . 1 2 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0u11d 51 ( S ) - 2 - ( 5 - br0m0thi0phen - 2 - y1 ) - 7 - hydr0xy - N - ( piperidin - 3 - NH y1 ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0xamide O NH N W E S Br. 52 Q. 54 H2N. . . 2 - ( Bicyc10 [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydr0xy - N - ( ( S ) - piperidin - 3 - y1 ) - 1 H - benz0 [ d ] imidaz01e - 4 - carb 0xamide. 2 - ( Bicyc10 [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydr0xy - N - ( adamantane - 3 - y1amin0 ) - 1H - benZ0 [ d ] imidaz01e - 4 - carb0xa1nide. 2 - ( Thi0phene - 2 - y1 ) - 7 - hydr0Xy - N - ( adamantate - 3 - y1amin0 ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide. Oct. 27 , 2011. US 2011 / 0263566 A1 Oct. 27 , 2011. . . 1 3 TABLE 1 - c0ntinued EXamp1e N0. Structure C0mp0u11d 55 NH2 N - ( 3 - Amin0cyc10hexy1 ) - 2 - ( bicyc10 [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - Q hydr0Xy - 1 H - benz0 [ d ] imidaz01e - 4 - carb0xamide O NH N \. N. H OH. 5 6 NH2 N - { [ ( cis ) —4 - Amin0cyc10heXy1 ] methy1 } - 2 - ( bicyc10 [ 2.2 . 1 ] heptan - 2 - y1 ) - 7 - hydr0xy - 1 H - benZ0 [ d ] imidaz01e - 4 - HvO / carboxamide O : N OH. 57 ( S ) - 7 - hydr0xy - 2 - ( 5 - ( piperazin - 1 - y1 ) thi0phen - 2 - y1 ) - N - QH ( piperidin - 3 - y1 ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide. mz / Z. 5 8 ( R ) - 7 - hydr0xy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thi0phen - 2 - y1 methy1 ) - 1H - benz0 [ d ] imidaz01e - 4 - carb0Xamide H O N\\\\\‘ , . - O\1H. . OH. US 2011 / 0263566 A1. Oct. 27 , 2011. . . . . 1 4 TABLE 1 - continued Examp1e No. Structure Compound 59 ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1methy1 ) - NH 1H - benzo [ d ] imidazo1e - 4 - carboxamide O NH 60 ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide O [ 0053 ] The compound of fo1mu1a ( 1 ) of the present inVen - . tion may be in the form of a pharmaceutica11y acceptab1e sa1t deriVed from an inorganic or organic acid , and representatiVe examp1es of the pharmaceutica11y acceptab1e sa1t deriVed from an inorganic or organic acid inc1ude sa1ts obtained by adding an inorganic acid such as hydroch10ric acid , hydrobromic acid , phosphoric acid or su1fonic acid , or organic carboxy1ic acids such as acetic acid , triﬁuoroacetic acid , citric acid , formic acid , ma1eic acid , oxa1ic acid , succinic acid , benzoic acid , tartaric acid , fumaric acid , mande1ic acid , ascorbic acid or ma1ic acid , methanesu1fonic acid , or para to1uene - su1fonic acid , Which do not 1imit its scope , to the compound of formu1a ( 1 ) . Such acids may be prepared by the conVentiona1 processes , and other acids , Which themse1Ves are not phar111a - ceutica11y acceptab1e , inc1uding oxa1ic acid may be emp1oyed in the preparation of the sa1ts. [ 0054 ] A1tematiVe1y , the compound of formu1a ( 1 ) of the present inVention may a1so be in the form of a pha1maceuti - ca11y acceptab1e sa1t deriVed from an inorganic or organic base inc1ude sa1ts obtained by adding an inorganic or organic base. For examp1e , a1ka1is inc1uding sodium hydroxide or potassium hydroxide , or a1ka1ine earth meta1 hydroxides inc1uding ca1cium hydroxide , magnesium hydroxide , a1uminum hydroxide or ammonium hydroxide may be used for the preparation of inorganic sa1t of the compound. Further , organic bases inc1uding triethy1amine or diisopropy1ethy - 1amine may a1so be used for the preparation of organic sa1t of the compound. [ 0055 ] The preferred inVentiVe compound of formu1a ( 1 ) may be prepared as in Scheme ( 1 ) . Scheme 1 O OCH3 O OCH3 XCN NH NaOC1 p - TSA i then NaHCO3 NH2 N X H OCH3 OCH3 A B. US 2011 / 0263566 A1 Oc - ontinued ocH3 oH Na___oH N\>_X . 1 ocH3C OCH3. BBI3l. O OH H2N — ( CH2 ) , — M N\>7X EDC , HOBt N H OH E. Wherein , p - TSA is p - to1uenesu1fonic acid , HATU is 2 - ( 1H - 7 - AZabenzotriazo1 - 1 - y1 ) - 1 , 1 , 3 , 3 - tetramethy1 uronium hexaﬁuorophosphate Methanaminium , D1PEA is N , N - diisopropy1ethy1amine , EDC is 1 - [ 3 - ( dimethy1aminopropy1 ) - 3 - ethy1carbodiimide , HOBt is 1 - hydroxybenzotriazo1e and X , a , and M haVe the same meaning as deﬁned preVious1y. [ 0056 ] Ani1ine A is reacted With the requisite nitri1e in the presence of p - to1uenesu1fonic acid to afford amidine B. Ami - di11e B is ch1orinated With sodium hypoch10rite and cyc1ized using sodium bicarbonate to form benzimidazo1e C. 1ntermediate C is saponiﬁed With sodium hydroxide to afford methoxy acid D Which is reacted With Various amines in the presence of HATU to afford amides F. Amides F are treated With boro11tribromide to afford compounds of formu1a ( 1 ) .111termediate C is treated With boron tribromide to afford hydroxy acid E Which is reacted With Various amines using EDC and HOBt to afford compounds of formu1a ( 1 ) . [ 0057 ] According1y , the present inVention proVides a method for preparing the compound of the present inVention , Which inc1udes the steps of : . [ 0058 ] contacting a carboxya1ky1 substituted ani1ine deriVatiVe With a nitri1e in the presence of an acid to form an intermediate amidine ; . [ 0059 ] cyc1izing the intermediate amidine to form a benzimidazo1e deriVatiVe haVing a carboxya1ky1 ; . [ 0060 ] saponifying the carboxya1ky1 of the benzimida - zo1e deriVatiVe to form a carboxy1ic acid ; and. [ 0061 ] contacting the carboxy1ic acid of the benzimida - zo1e deriVatiVe With an amine deriVatiVe , to obtain the compound of the present inVention. [ 0062 ] As used herein , the term “contacting” refers to the process of bringing into contact at 1east tWo distinct species such that they can react. 1t shou1d be appreciated , hoWeVer , the resu1ting reaction product can be produced direct1y from. Oct. 27 , 2011. H2N— C ( H ) 2 —M. HATU , D1PEA. a reaction betWee11 the added reagents or from an intermediate from one or more of the added reagents Which can be produced in the reaction mixture. O©\1Boc. 1. Cu1 , Cu , K3PO4 , amine 2. TFA = N S M N \ H. Scheme 11. . US 2011 / 0263566 A1. [ 0063 ] Compound T is reacted With the requisite amine in the presence of copper and copper ( 1 ) iodide fo11oWed by deprotection to afford compound U ( Scheme 11 ) . [ 0064 ] A sa1t , hydrate , so1Vate and isomer of the inVentiVe compound of formu1a ( 1 ) may be prepared by emp1oying any of the knoWn methods. The inVentiVe compound of formu1a ( 1 ) , a sa1t , hydrate , so1Vate or isomer thereof may be used for the treatment of PBK dependent diseases such as cancer , by Way of inhibiting PBK actiVity , the inVentiVe compound haVing an 1C50 Va1ue ( micro M ) , genera11y in the range of 0.0001 to 100 , for examp1e 0.001 to 50 , preferab1y 0.001 to 10 , more preferab1y 0.001 to 5. [ 0065 ] According1y , the present inVention inc1udes a pharmaceutica1 composition Which inc1udes a therapeutica11y effectiVe amount of the compound of formu1a ( 1 ) , a sa1t , hydrate , so1Vate or isomer thereof as an actiVe ingredient and a pha1maceutica11y acceptab1e carrier ; therefore , the pha1maceutica1 composition of the present inVention exerts superior preVentiVe and treating effects on PBK dependent diseases. [ 0066 ] A pharmaceutica1 formu1ation may be prepared in accordance With any of the conVentiona1 procedures. 1n preparing the formu1ation , the actiVe ingredient is preferab1y admixed or di1uted With a carrier , or enc1o sed Within a carrier , sachet or other container. When the carrier serVes as a di1uent , it may be a so1id , semi - so1id or 1iquid materia1 acting as a Vehic1e , excipient or medium for the actiVe ingredient. Thus , the formu1ations may be in the form of a tab1et , pi11 , poWder , sachet , e1ixir , suspension , emu1sion , so1ution , syrup , aeroso1 , soft and hard ge1atin capsu1e , steri1e injectab1e so1ution , ster - i1e packaged poWder and the 1ike. [ 0067 ] Examp1es of suitab1e carriers , excipients , and di1u - ents are 1actose , dextrose , sucrose , sorbito1 , mannito1 , ca1 - cium si1icate , ce11u1ose , methy1 ce11u1ose , microcrysta11ine ce11u1ose , po1yViny1pyrro1idone , Water , and minera1 oi1. The formu1ations may additiona11y inc1ude ﬁ11ers , antiemu1siﬁers , preserVatiVes and the 1ike. The compositions of the inVention may be formu1ated so as to proVide quick , sustained or de1ayed re1ease of the actiVe ingredient after their administration to a mamma1 by emp1oying any of the procedures We11 knoWn in the art. [ 0068 ] The pharmaceutica1 composition of the present inVention can be administered Via Various routes inc1uding ora1 , transderma1 , subcutaneous , intraVenous and intramus - cu1ar introduction. [ 0069 ] 1n addition to the aboVe , the present composition may contain other pharmaceutica1 actiVe ingredients so 10ng as they do not inhibit the in ViVo ﬁ1nction of the compound of the present inVention. For examp1e , the composition may further contain chemotherapeutic agents conVentiona11y used for treating cancers. [ 0070 ] The compounds disc1o sed herein can be used to treat or preVent PBK dependent diseases inc1uding cancer. 1t has been shoWn that PBK is a potentia1 target for treating cancers , such as breast cancer ( Examp1e 73 of the present speciﬁcation ) , b1adder cancer ( WO2006 / 085 684 ) , and sma11 ce11 1ung cancer ( WO2007 / O13665 ) . According1y , the cancer to be targeted inc1ude , but are not 1imited to , breast cancer , b1adder cancer , and sma11 ce11 1ung cancer. For examp1e , the present. Oct. 27 , 2011. inVention proVides methods for treating or preVenting PBK dependent diseases inc1uding cancer in a subject by administering to said subject the compounds disc1osed herein. 1n a preferred embodiment , such compound can be administered to the subject in the form of pharmaceutica1 composition inc1uding the compound of the present inVention and pharmaceutica11y or physio1ogica11y acceptab1e carrier. The pharmaceutica1 composition of the present inVention can be administered Via Various routes inc1uding ora1 , transderma1 , subcutaneous , intraVenous and intramuscu1ar introduction for treating a PBK dependent diseases inc1uding cancer in a subject. [ 0071 ] 1n another embodiment , the present inVention a1so proVides the use of the compound of the present inVention in manufacturing a pharmaceutica1 composition for treating a PBK dependent diseases inc1uding cancer. For examp1e , the present inVention re1ates to a use of the compound of the present inVention for manufacturing a pharmaceutica1 composition for treating a PBK dependent diseases inc1uding cancer. 1n addition , the present inVention further proVides the compound of the present inVention for use in treating a PBK dependent diseases inc1uding cancer. [ 0072 ] A1tematiVe1y , the present inVention further proVides a method or process for manufacturing a pharmaceutica1 composition for treating PBK dependent diseases inc1uding cancer , Wherein the method or process inc1udes a step for formu1ating a pharmaceutica11y or physio1ogica11y accept - ab1e ca1rier With the compound of the present inVention as actiVe ingredients. [ 0073 ] 1n another embodiment , the present inVention a1so proVides a method or process for manufacturing a pharmaceutica1 composition for treating a PBK dependent diseases inc1uding cancer , Wherein the method or process inc1udes a step for admixing an actiVe ingredient With a pha1maceuti - ca11y or physio1ogica11y acceptab1e carrier , Wherein the actiVe ingredient is the compound of the present inVention. [ 0074 ] The dosage and method of administration Vary according to the body - Weight , age , and symptoms of the patient ; hoWeVer , one ski11ed in the art can suitab1y se1ect them. [ 0075 ] For examp1e , a1though the dose of a compound of the present inVention that regu1ates its actiVity depends on the symptoms , the dose is genera11y about 0.1 mg to about 100 mg per day , preferab1y about 1.0 mg to about 50 mg per day and more preferab1y about 1.0 mg to about 20 mg per day , When administered ora11y to a norma1 adu1t human ( Weight 60 kg ) . [ 0076 ] When administering the compound parentera11y , in the form of an injection to a norma1 adu1t human ( Weight 60 kg ) , a1though there are some differences according to the patient , target organ , symptoms and method of administration , it is conVenient to intraVenous1y inject a dose of about 0.01 mg to about 30 mg per day , preferab1y about 0.1 to about 20 mg per day and more preferab1y about 0.1 to about 10 mg per day. 1n the case of other anima1s , the appropriate dosage amount may be routine1y ca1cu1ated by conVerting to 60 kg of body - Weight. EXAMPLES. [ 0077 ] The fo11oWing examp1es are intended to further i11ustrate the present inVention Without 1imiting its scope. US 2011 / 0263566 A1. Examp1e 1. Step 1 : Synthesis of Methy1 4 - Methoxy - 3 - ( thiophene - 2 - carboximidamido ) benzoate. [ 0072 ; ] . O OCH3 °HC1. NH. 8 N H. OCH3 l / . [ 0079 ] p - To1uenesu1fonic acid monohydrate ( 42 g , 110 mmo1 ) Was heated at 120 degrees C. and once the so1id com - p1ete1y me1ted , it Was p1aced under high Vacuum for 1 h to remoVe the Water. The Vacuum Was re1eased , ani1ine ( 20 g , 5 5 mmo1 ) and 2 - thiophenecarbonitri1e ( 24 g , 110 mmo1 ) Were added , and the reaction mixture Was heated at 160 degrees C. for 4 h. 1he reaction mixture Was coo1ed to room temperature fo11oWed by addition of satd. aq NaHCO3 ( 250 mL ) and ethy1 acetate ( 250 mL ) . The 1ayers Were separated , the aqueous 1ayer Was extracted With ethy1 acetate ( 100 mL ) , and the combined organic 1ayers Were dried oVer Na2SO4 , ﬁ1tered , and concentrated. The crude residue Was puriﬁed by co1umn chromatography to obtain 16 g of the crude amidine intermediate. The crude intermediate Was disso1Ved in ethy1 acetate ( 350 mL ) and HC1 ( 2.0 M in diethy1 ether , 55 mL , 1 10 mmo1 ) Was added. The resu1ting precipitate Was ﬁ1tered to obtain the desired product ( 16 g , 42% yie1d ) as an off - White so1id : ES1 MS m / z 291 [ Cl4Hl4N3O2S + H ] + . Step 2 : Synthesis of Methy1 7 - Methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate. [ 0080 ] . o ocH3 N s W N \. [ 0081 ] To a so1ution of the product from step 1 ( 16 g , 49 mmo1 ) in methano1 ( 100 mL ) Was added 5% aq NaOC1 ( 75 mL , 55 mmo1 ) and the reaction mixture Was stirred at room temperature for 2 h. Next , satd. aq NaHCO3 ( 150 mL ) and methano1 ( 150 mL ) Were added and the resu1ting reaction mixture Was heated at 60 degrees C. for 2 d. The reaction mixture Was coo1ed to room temperature and concentrated to remoVe methano1. The reaction mixture Was acidiﬁed to pH 4 using 6 N HC1 and the resu1ting precipitate Was ﬁ1tered and dried to obtain the desired product ( 8 g , 57% yie1d ) as a broWn so1id : 1H NMR ( 500 MHz , CDC13 ) de1ta 7.86 ( d , J : 8.5 Hz , . ocH3. Oct. 27 , 2011. 1H ) , 7.71 - 7.68 ( m , 1H ) , 7.48 - 7.45 ( m , 1H ) , 7.17—7.14 ( m , 1H ) , 7.73 ( d , J=8.5 Hz , 1H ) , 4.16 ( m , 3H ) , 3.921 ( m , 3H ) ; ES1 Ms m / z 2s9 [ Cl , Hl2N2O3S + H ] + . Step 3 : Synthesis of 7 - Methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 00s2 ] . oCH3. [ 0083 ] To a so1ution of the product from step 2 ( 4.2 g , 14 mmo1 ) in ethano1 ( 30 mL ) and Water ( 15 mL ) Was added 6 N NaOH ( 55 mL ) and the reaction mixture Was heated at 90 degrees C. for 2 h. 1he reaction mixture Was coo1ed and concentrated to dryness. The crude residue Was disso1Ved in Water ( 30 m1 ) and acidiﬁed to pH 4 using 6 N HC1. The resu1ting precipitate Was ﬁ1tered and dried to obtain the desired product ( 2.2 g , 58% yie1d ) as a broWn so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 8.25 ( d , J=3.0 Hz , 1H ) , 7.77 ( d , J : 8.0 Hz , 1H ) , 7.73 - 7.68 ( 111 , 11 - 1 ) , 7.22 - 7.18 ( m , 1H ) , 6.82 ( d , J=8.5 Hz , 1H ) , 3.97 ( m , 3H ) ; ES1 MS m / z 275 [ C13H1oN2O3S + H1 + - . Step 4 : Synthesis of 7 - Methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. mm. [ 0085 ] To a so1ution of the product from step 3 ( 2.5 g , 9.1 mmo1 ) in dich1oroethane ( 100 mL ) Was added BBr3 ( 23 g , 91 mmo1 ) and the reaction mixture Was heated at 90 degrees C. for 2 d. The reaction mixture Was coo1ed and poured onto ice. The resu1ting so1ids Were ﬁ1tered to obtain the desired product ( 0.45 g , 19% yie1d ) as a broWn so1id. 1he ﬁ1trate Was acidiﬁed to pH 4 using 6 N HC1 and the resu1ting precipitate Was ﬁ1tered to obtain a second batch of the desired product ( ALB 128328 , 1.6 g , 88% yie1d ) as a broWn so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.93 - 7.90 ( m , 1H ) , 7.75 ( d , J=8.5 Hz , 1H ) , 7.62 - 7.58 ( m , 1H ) , 7.19 - 7.14 ( m , 1H ) , 6.65 ( d , J : 8.1 Hz , 1H ) ; ES1 MS m / z 261 [ C12H8N2O3S + H ] + . OH. US 2011 / 0263566 A1 Oct. 27 , 2011. 18. sodium hydroxide to afford the desired product ( 1.7 g crude ) . Examp1e 2 as a b1ack so1id : ES1 MS m / z 233 [ C12H12N2O3 + H ] + . Step 1 : Synthesis of Methy1 3 - ( Cyc1opropanecarboximidamido ) - 4 - methoxybenzoate Hydroch1oride. [ 0086 ] . O OH °HC1. NH H. oCH3 [ 0087 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 3 - amino - 4 - methoxybenzoate ( 10 g , 55 mmo1 ) Was reacted With cyc1opropanecarbonitri1e ( 7.4 g , 1 10 mmo1 ) to afford the desired product ( 16 g crude ) as a b1ack so1id : ES1 MS m / z 249 [ C13H16N2O3 + H ] + . Step 2 : Synthesis of Methy1 2 - Cyc1opropy1 - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate. [ 0088 ] o ooH3 N E oCH3. [ 0089 ] Fo11oWing the procedure out1ined for step 2 in Examp1e 1 , methy1 3 - ( cyc1opropanecarboximidamido ) - 4 - methoxybenzoate hydroch1oride ( 15 g , 50 mmo1 ) Was reacted With aq NaOC1 fo11oWed by satd. aq NaHCO3 to afford the desired product ( 12 g crude ) as a broWn so1id : ES1 MS m / z. 247 [ Cl3H , 4N2O3 + H ] + . Step 3 : Synthesis of 2 - Cyc1opropy1 - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0090 ] . O OH. N NN. ocH3. [ 0091 ] Fo11oWing the procedure out1ined for step 3 in Examp1e 1 , methy1 2 - cyc1opropy1 - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate ( 2.0 g , 8.0 mmo1 ) Was reacted With. Step 4 : Synthesis of 2 - Cyc1opropy1 - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0092 ] . N NN. OH. [ 0093 ] Fo11oWing the procedure out1ined for step 4 in Examp1e 1 , 2 - cyc1opropy1 - 7 - methoxy - 1H - benzo [ d ] imida - zo1e - 4 - carboxy1ic acid ( 1.5 g , 6.1 mmo1 ) Was reacted With boron tribromide to afford the desired product ( 1.2 g crude ) as a b1ack so1id : ES1 MS m / z 219 [ Cl1Hl0N2O3 + H ] + . Examp1e 3. Step 1 : Synthesis of Methy1 3 - ( Cyc1opentanecarboximidamido ) - 4 - methoxybenzoate Hydroch1oride. [ 0094 ] . o ooH3 °HC1. NH. 46. [ 0095 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 3 - amino - 4 - methoxybenzoate ( 5.0 g , 27 mmo1 ) Was reacted With cyc1opentanecarbonitri1e ( 5.2 g , 55 mmo1 ) to afford the desired product ( 7.7 g crude ) as a broWn so1id : ES1 MS m / z 277 [ C15H20N2O3 + H ] + . ocH3. Step 2 : Synthesis of Methy1 2 - Cyc1openty1 - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate. [ 0096 ] . o oCH3. N W 8 oCH3. [ 0097 ] Fo11oWing the procedure out1ined for step 2 in Examp1e 1 , methy1 3 - ( cyc1opentanecarboximidamido ) - 4 - methoxybenzoate hydroch1oride ( 5.6 g , 18 mmo1 ) Was. US 2011 / 0263566 A1. reacted With aq NaOC1 fo11oWed by satd aq NaHCO3 to afford the desired product ( 4.9 g crude ) as a b1ack so1id : ES1 MS m / z 275 [ C15Hl8N2O3 + H ] + . Step 3 : Synthesis of 2 - Cyc1openty1 - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0098 ] . N m 8. [ 0099 ] Fo11oWing the procedure out1ined for step 4 in Examp1e 1 , methy1 2 - cyc1openty1 - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate ( 1.1 g , 4.0 mmo1 ) Was reacted With boron tribromide to afford the desired product ( 0.92 g crude ) as a b1ack so1id : ES1 MS m / z 247 [ C13Hl4N2O3 + H ] + . OH. Examp1e 4. Step 1 : Synthesis of Methy1 3 - Benzimidamido - 4 - methoxybenzoate Hydroch1oride. [ 0100 ] . o ooH3 - Hc1. NH. N H 0 ( 3HN Jb. [ 0101 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 3 - amino - 4 - methoxybenzoate ( 5.0 g , 27 mmo1 ) Was reacted With benzonitri1e ( 5.7 g , 55 mmo1 ) to afford the desired product ( 7.8 g crude ) as a b1ack so1id : ES1 MS m / z 285 [ Cl6Hl6N2O3 + H ] + . Step 2 : Synthesis of Methy1 7 - Methoxy - 2 - pheny1 - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate [ 0102 ] o OCH3 N @ E. ocH3. Oct. 27 , 2011. [ 0103 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 3 - benzimidamido - 4 - methoxybenzoate hydroch10ride ( 2.0 g , 8.0 mmo1 ) Was reacted With aq. [ 0104 ] NaOC1 fo11oWed by satd aq NaHCO3 to afford the desired product ( 1.7 g crude ) as an off - White so1id : ES1 MS m / z 283 [ Cl6Hl4N2O3 + H ] + . Step 3 : Synthesis of 7 - Hydroxy - 2 - pheny1 - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0105 ] . H3. [ 0106 ] Fo11oWing the procedure out1ined for step 4 in Examp1e 1 , methy1 7 - methoxy - 2 - pheny1 - 1H - benzo [ d ] imida - zo1e - 4 - carboxy1ate ( 4.0 g , 12 mmo1 ) Was reacted With boron. mz. OH. tribromide to afford the desired product ( 2.1 g crude ) as a b1ack so1id : ES1 MS m / z 255 [ C14H1ON2O3 + H ] + . Genera1 Procedure A7Synthesis of Compounds of Formu1a ( 1 - 11 ) as Described in Scheme ( 1 ) : . [ 0107 ] To a so1ution of hydroxy acids E ( 1.0 equiV ) in THF ( 5 - 10 mL ) Was added EDC ( 1.2 equiV ) , HOBt ( 1.1 equiV ) , and the amine ( 1.2 equiV ) and the reaction mixture Was either stirred at room temperature for 16 h or heated at 50 - 70 degrees C. for 16 h. 1he reaction mixture Was di1uted With ethy1 acetate ( 50 mL ) and Washed With Water ( 25 m1 ) . The 1ayers Were separated and the organic 1ayer Was dried oVer Na2SO4 , concentrated , and puriﬁed by preparatiVe HPLC ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . 1n some instances the desired product Was disso1Ved in triﬁuoroacetic acid ( 2 mL ) and stirred for 1 h at room temperature. The reaction mixture Was concentrated and e1uted through an ion - exchange co1umn ( using methano1 and 7 N methano1 in ammonia ) to obtain the desired products. Examp1e 5. 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. NH 0 %\ / © N\ NM. [ 0108 ] . OH. US 2011 / 0263566 A1. [ 0109 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 4 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford the desired product ( 21 mg , 27% yie1d ) as a 11ght broWn - ye11oW so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 9.67 ( bs , 1H ) , 7.57 ( d , J : 8.0 Hz , 1H ) , 6.58 ( d , J : 8.0 Hz , 1H ) , 3.25 - 3.22 ( m , 2H ) , 2.98 - 2.96 ( m , 2H ) , 2.48 - 2.46 ( m , 2H ) , 2.16 ( bs , 1H ) , 1.68 - 1.58 ( m , 3H ) , 1.18 - 1.06 ( m , 6H ) ; ES1 MS m / z 315 [ Cl7H22N4O2 + H ] + ; HPLC 98.6% ( AUC ) , tR : 6.38 min. Examp1e 6. 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 - methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. [ 0110 ] N\> Q 8. OH. [ 0111 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 3 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford the desired product ( 12 mg , 15% yie1d ) as a 1ight gray so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.66 ( d , J : 8.0 Hz , 1H ) , 6.57 ( d , J : 8.0 Hz , 1H ) , 3.51 - 3.49 ( m , 2H ) , 3.14 ( d , J : 12.5 Hz , 1H ) , 2.94 ( bs , 1H ) , 2.75 - 2.73 ( m , 1H ) , 2.19 - 2.17 ( m , 1H ) , 1.90 - 1.88 ( m , 2H ) , 1.71 - 1.68 ( m , 2H ) , 1.54 - 1.49 ( m , 1H ) , 1.35 ( bs , 1H ) , 1.15 - 1.13 ( m , 4H ) ; ES1 MS m / z 315 [ Cl7H22N4O2 + H ] + ; HPLC 99.7% ( AUC ) , tR : 5.98 min. Examp1e 7. 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. H N\ NM. [ 0112 ] . OH. [ 0113 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 2 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford. Oct. 27 , 2011. the desired product ( 13 mg , 17% yie1d ) as a 11ght gray so1id : 1H NMR ( 50O MHz , CD3OD ) de1ta 7.66 ( d , J : 8.0 Hz , 1H ) , 6.56 ( d , J : 8.0 Hz , 1H ) , 3.39 - 3.38 ( m , 2H ) , 3.22 ( d , J : 12 Hz , 1H ) , 3.08 ( d , J=12 Hz , 11 - 1 ) , 2.69 - 2.68 ( m , 1H ) , 2.66 - 2.63 ( m , 1H ) , 2.55 - 2.50 ( m , 1H ) , 2.18 - 2.15 ( m , 1H ) , 1.99 - 1.97 ( m , 2H ) , 1.92 - 1.89 ( m , 1H ) , 1.82 - 1.80 ( m , 1H ) , 1.62 - 1.59 ( m , 1H ) , 1.32 - 1.34 ( m , 1H ) , 1.13 ( bs , 4H ) ; ES1 MS m / z 315 [ C , 7H22N4O2 + H ] + ; HPLC 96.8% ( AUC ) , ER : 6.78 min. Examp1e 8. 2 - cyc1opropy1 - 4 - hydroxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. [ 0114 ] . CH3. N NN. OH. [ 0115 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic 1 - methy1piperidin - 3 - amine ( 43 mg , 0.38 mmo1 ) to afford the desired product ( 21 mg , 32% yie1d ) as a broWn - ye11oW so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 12.7 ( bs , 1H ) , 10.5 ( bs , 1H ) , 9.97 ( bs , 1H ) , 7.58 ( d , J : 8.0 Hz , 1H ) , 6.61 ( d , J : 8.0 Hz , 1H ) , 4.06 ( bs , 1H ) , 3.32 ( bs , 2H ) , 2.40 - 2.34 ( m , 1H ) , 2.22 - 2.11 ( m , 2H ) , 1.75 ( bs , 11 - 0 , 1.65 ( bs , 1H ) , 1.55 ( bs , 1H ) , 1.44 ( bs , 1H ) , 1.14 - 1.10 ( m , 4H ) ; ES1 MS m / z 315 [ Cl7H22N4O2 + H ] + ; HPLC 96.8% ( AUC ) , tR=7.12 min. Examp1e 9. ( S ) - 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. [ 0116 ] . NH. N NN. OH. US 2011 / 0263566 A1. [ 0117 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With ( S ) - tert - buty1 3 - aminopiperidine - 1 - carboxy1ate ( 75 mg , 0.38 mmo1 ) to afford the desired product ( 28 mg , 37% yie1d ) as a broWn - ye11oW so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 12.7 ( bs , 1H ) , 9.82 ( bs , 1H ) , 7.58 ( d , J : 8.5 Hz , 1H ) , 6.61 ( d , J : 8.5 Hz , 1H ) , 3.93 - 3.91 ( m , 1H ) , 3.17 ( bs , 1H ) , 3.03 - 3.00 ( m , 1H ) , 2.77 ( m , 1H ) , 2.64 ( bs , 1H ) , 2.16 ( bs , 1H ) , 1.87 ( bs , 1H ) , 1.73 - 1.70 ( m , 1H ) , 1.50 - 1.45 ( m , 2H ) , 1.11 - 1.10 ( m , 4H ) ; ES1 MS m / z 301 [ Cl6H20N4O2 + H ] + ; HPLC 96.8% ( AUC ) , tR=6.63 min. Examp1e 10. 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. 9. O NH. [ 0118 ] . N 1H. OH. [ 0119 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic ten - buty1 4 - aminopiperidine - 1 - carboxy1ate ( 75 mg , 0.38 mmo1 ) to afford the desired product ( 27 mg , 36% yie1d oVer tWo steps as a broWn - ye11oW so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 9.75 ( d , J : 6 Hz , 1H ) , 7.59 ( d , J : 8.5 Hz , 1H ) , 6.61 ( d , J : 8.5 Hz , 1H ) , 3.96 ( bs , 1H ) , 2.99 - 2.97 ( m , 2H ) , 2.70 - 2.66 ( m , 2H ) , 2.16 ( bs , 1H ) , 1.88 - 1.86 ( m , 2H ) , 1.42 - 1.40 ( m , 2H ) , 1.13 - 1.04 ( m , 4H ) ; ES1 MS m / z 301 [ C16H20N4O2 + H ] + ; HPLC 95.8% ( AUC ) , tR : 6.21 min. Examp1e 11. 2 - cyc1opropy1 - 4 - hydroxy - N - ( pipe1idin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. N. O NH. [ 0120 ] . N 1H. OH. Oct. 27 , 2011. [ 0121 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 3 - aminopiperidine - 1 - carboxy1ate ( 75 mg , 0.38 mmo1 ) to afford the desired product ( 16 mg , 21% yie1d ) as a broWn - ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.67 ( d , J=8.0 Hz , 1H ) , 6.6O ( d , J : 8.0 Hz , 1H ) , 4.12 - 4.08 ( m , 1H ) , 3.31 - 3.28 ( m , 1H ) , 3.04 - 3.00 ( m , 1H ) , 2.79 - 2.73 ( m , 1H ) , 2.20 - 2.10 ( m , 2H ) , 1.94 - 1.91 ( m , 1H ) , 1.76 - 1.65 ( m , 1H ) , 1.17 - 1.14 ( m , 4H ) ; ES1 MS m / z 301 [ Cl6H2ON4O2 + H ] + ; HPLC 96.8% ( AUC ) , tR : 6. 63 min. Examp1e 12. 2 - cyc1opropy1 - 4 - hydroxy - N - ( pyrro1idin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. 7. O NH. N NH. [ 0122 ] . OH. [ 0123 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 3 - aminopyrro1idine - 1 - carboxy1ate ( 70 mg , 0.38 mmo1 ) to afford the desired product ( 19 mg , 27% yie1d ) as a broWn - ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.66 ( d , J=8.0 Hz , 1H ) , 6.57 ( d , J : 8.0 Hz , 1H ) , 4.56 - 4.51 ( m , 1H ) , 3.36 - 3.32 ( m , 1H ) , 3.26 - 3.20 ( m , 1H ) , 3.14 - 3.09 ( m , 1H ) , 3.03 - 3.00 ( m , 1H ) , 2.32 - 2.25 ( m , 1H ) , 2.19 - 2.14 ( m , 1H ) , 1.97 - 1.93 ( m , 1H ) , 1.14 - 1.10 ( m , 4H ) ; ES1 MS m / z 287 [ C15H18N4O2 + H ] + ; HPLC 96.8% ( AUC ) , tR=6.40 min. Examp1e 13. N - ( azetidin - 3 - y1methy1 ) - 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. , , . O NH. [ 0124 ] . N NN. OH. [ 0125 ] Fo11oWing genera1 procedure A , 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , . US 2011 / 0263566 A1. 0.25 mmo1 ) Was reacted With tert - buty1 3 - ( aminomethy1 ) azetidine - 1 - carboxy1ate ( 70 mg , 03 8 mmo1 ) to afford the desired product ( 22 mg , 31% yie1d ) as a broWn - ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.66 ( d , J=8.5 Hz , 1H ) , 6.56 ( d , J : 8.5 Hz , 1H ) , 4.00 - 3.85 ( m , 4H ) , 3.69 - 3.67 ( m , 2H ) , 3.17 - 3.14 ( m , 1H ) , 2.18 - 2.14 ( m , 1H ) , 1.13 - 1.08 ( m , 4H ) ; ES1 MS m / z 287 [ C15H18N4O2 + H ] + ; HPLC 96.8% ( AUC ) , tR : 6. 15 min. Examp1e 14. Synthesis of 2 - cyc1openty1 - 4 - hydroxy - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. [ 0126 ] . O zm mz / 2 E mz. OH. [ 0127 ] Fo11oWing genera1 procedure A , 2 - cyc1openty1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 62 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 2 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford the desired product ( 33 mg , 39% yie1d ) as a broWn so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.69 ( d , J : 9.0 Hz , 1H ) , 6.59 ( d , J=9.0 Hz , 1H ) , 3.54 - 3.52 ( m , 2H ) , 3.39 - 3.34 ( m , 1H ) , 3.16 - 3.11 ( m , 1H ) , 2.99 - 2.93 ( m , 1H ) , 2.74 ( bs , 1H ) , 2.19 - 2. 15 ( m , 2H ) , 2.09 - 1.81 ( m , 6H ) , 1.78 - 1.69 ( m , 3H ) , 1.52 - 1.32 ( m , 3H ) ; ES1 MS m / z 343 [ Cl9H26N4O2 + H ] + ; HPLC 98.6% ( AUC ) , tR : 1.51 min. Examp1e 15. 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. O H\ / O\JH N W 8. [ 0128 ] . OH. [ 0129 ] Fo11oWing genera1 procedure A , 2 - cyc1openty1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 62 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 3 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford the desired product ( 35 mg , 41% yie1d ) as a off - White so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.69 ( d , J : 9.0 Hz , 1H ) , . Oct. 27 , 2011. 6.59 ( d , J : 9.0 Hz , 1H ) , 3.43 - 3.41 ( m , 2H ) , 3.30—3.25 ( m , 1H ) , 3.16 - 3.12 ( m , 1H ) , 2.72—2.59 ( m , 2H ) , 2.18—2.15 ( m , 2H ) , 2.03—1.75 ( m , 11H ) , 1.39—1.34 ( m , 1H ) ; ES1 Ms m / z 343 [ Cl9H26N4O2 + H ] + ; HPLC 99.2% ( AUC ) , tR=1.49 min. Examp1e 16. ( S ) - 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. [ 0130 ] . N m E. [ 0131 ] Fo11oWing genera1 procedure A , 2 - cyc1openty1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With ( S ) - tert - buty1 3 - aminopiperi - . OH. dine - 1 - carboxy1ate ( 75 mg , 0.38 mmo1 ) to afford the desired product ( 22 mg , 27% yie1d ) as a broWn so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.69 ( d , J=8.0 Hz , 1H ) , 6.61 ( d , J=8.0 Hz , 1H ) , 4.09 ( bs , 1H ) , 3.39 - 3.30 ( m , 2H ) , 2.99 ( bs , 1H ) , 2.72 - 2.76 ( m , 2H ) , 2.19 - 2.14 ( m , 3H ) , 2.03 - 1.99 ( m , 2H ) , 1.91 - 1.88 ( m , 3H ) , 1.78 - 1.67 ( m , 4H ) ; ES1 MS m / z 329 [ Cl8H24N4O2 + H ] + ; HPLC >99% ( AUC ) , tR : 1.48 min. Examp1e 17. ( S ) - 4 - Hydroxy - 2 - pheny1 - N - ( pipe1idin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. [ 0132 ] . OH. [ 0133 ] Fo11oWing genera1 procedure A , 4 - hydroxy - 2 - phe - ny1 - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 55 mg , 0.25 mmo1 ) Was reacted With ( S ) - tert - buty1 3 - aminopiperidine - 1 - carboxy1ate ( 75 mg , 0.38 mmo1 ) to afford the desired product ( 10 mg , 12% yie1d ) as a green - ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 8.20 - 8.18 ( m , 2H ) , 7.78 ( d , J : 8.5 Hz , 1H ) , 7.56 - 7.51 ( m , 3H ) , 6.68 ( d , J : 8.5 Hz , 1H ) , 4.16 ( bs , 1H ) , . US 2011 / 0263566 A1. 3.39—3.35 ( m , 1H ) , 3.05 ( bs , 1H ) , 2.87—2.82 ( m , 2H ) , 2.202 19 ( m , 1H ) , 2.00 ( bs , 1H ) , 1.80 - 1.76 ( m , 2H ) ; ES1MSm / z337 [ C , 9H , 0N4O2 + H ] + ; HPLC 95.7% ( AUC ) , tR : 8.78 min. Examp1e 18. 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. H N @ H. [ 0135 ] Fo11oWing genera1 procedure A , 4 - hydroxy - 2 - phe - ny1 - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 62 mg , 0.25 mmo1 ) Was reacted With racemic tert - buty1 2 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford the desired product ( 20 mg , 23% yie1d ) as a broWn so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 9.77 ( bs , 1H ) , 8.32 - 8.30 ( m , 2H ) , 7.70 ( d , J=8.5 Hz , 1H ) , 7.58 - 7.51 ( m , 3H ) , 6.71 ( d , J=8.5 Hz , 1H ) , 3.17 - 3.10 ( m , 2H ) , 2.96 - 2.94 ( m , 1H ) , 2.56 - 2.42 ( m , 3H ) , 1.90 - 1.87 ( m , 1H ) , 1.81 - 1.77 ( m , 1H ) , 1.69 - 1. 65 ( m , 1H ) , 1.46 - 1.44 ( m , 1H ) , 1.27 - 1.24 ( m , 1H ) ; ES1 MS m / z 351 [ C2OH22N4O2 + H ] + ; HPLC 99.0% ( AUC ) , tR : 7.74 mm. [ 0134 ] . OH. Examp1e 19. 4 - hydroxy - 2 - pheny1 - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. O H\ / O\1H N XC2 N. [ 0137 ] Fo11oWing genera1 procedure A , 4 - hydroxy - 2 - phe - ny1 - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 62 mg , 0.25 mmo1 ) Was reacted With tert - buty1 3 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 81 mg , 0.38 mmo1 ) to afford the desired product ( 20 mg , 23% yie1d ) as a broWn so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 9.99 ( bs , 1H ) , 8.40 - 8.38 ( m , 2H ) , 7.70 ( d , J : 8.5 Hz , 2H ) , 7.57 - 7.52 ( m , 3H ) , 6.72 ( d , J : 8.5 Hz , 1H ) , 3.43 - 3.41 ( m , 2H ) , 3.11 - 3.08 ( m , 1H ) , 2.64 ( bs , 1H ) , 1.78 - 1. 71 ( m , 2H ) , 1.57 ( bs , 1H ) , 1.69 - 1.65 ( m , 1H ) , 1.46 - 1.44 ( m , . [ 0136 ] . OH. Oct. 27 , 2011. 1H ) , 1.27—1.24 ( m , 1H ) ; ES1 Ms m / z 351 [ C , , H , , N , o , + H ] + ; HPLC 99.1 ( AUC ) , tR : 8.99 min. Examp1e 20. 7 - Hydroxy - N - ( 4 - hydroxycyc1ohexy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0138 ] . [ 0139 ] To a so1ution of 4 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.15 g , 0.57 mmo1 ) in DMF ( 10 mL ) Was added HATU ( 0.26 g , 0.68 mmo1 ) , D1PEA ( 0.30 mL , 1.7 mmo1 ) and trans - 4 - aminocyc1ohexano1 ( 0.13 g , 1.1 mmo1 ) . The reaction mixture Was heated at 50 degrees C. for 16 h. The reaction mixture Was di1uted With satd. aq NaHCO3 ( 20 mL ) and extracted With ethy1 acetate ( 3x20 mL ) . The combined organic 1ayer Was dried oVer Na2SO4 , concentrated , and puriﬁed by preparatiVe HPLC ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The desired product Was obtained as the triﬁuoroacetic acid sa1t Which Was e1uted through an ion - exchange co1umn ( using methano1 and 7 N methano1 in ammonia ) to afford the desired product ( 13 mg , 32% ) as an off - White so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 10.19 - 10.17 ( m , 1H ) , 7.87 - 7.85 ( m , 1H ) , 7.79 - 7.75 ( m , 1H ) , 7.64 - 7.61 ( m , 1H ) , 7.22 - 7.19 ( m , 1H ) , 6.71 - 6. 67 ( m , 1H ) , 4.02 - 3.97 ( m , 1H ) , 3.77 - 3.71 ( m , 1H ) , 2.19 - 2.08 ( m , 4H ) , 1.55 - 1.50 ( m , 4H ) ; ES1 MS m / z 358 [ Cl8Hl9N3O3S + H ] + ; HPLC 98.8% ( AUC ) , tR : 11.84 min. mz o / — / - N : ; —< : >. Examp1e 21. ( 7 - hydroxy - 2 - [ thiophen - 2 - y1 ] - 1 H - benzo [ d ] imidazo1 - 4 - y1 ) ( piperazin - 1 - y1 ) methanone. [ 0140 ] . OH. US 2011 / 0263566 A1. [ 0141 ] To a so1ution of 4 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.20 g , 0.76 mmo1 ) in DMF ( 10 mL ) Was added HATU ( 0.34 g , 0.92 mmo1 ) , D1PEA ( 0.39 mL , 2.3 mmo1 ) and tert - buty1 piperazine - 1 - carboxy1ate ( 0.17 g , 0.92 mmo1 ) . The reaction mixture Was heated at 50 degrees C. for 16 h. The reaction mixture Was di1uted With satd. aq NaHCO3 ( 20 mL ) and extracted With ethy1 acetate ( 3x20 mL ) . The combined organic 1ayer Was dried oVer Na2SO4 , concentrated , and puriﬁed by preparatiVe HPLC ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The intermediate Was disso1Ved in methy1ene dich1oride and treated With 2 N HC1 in ether and the reaction mixture Was stirred at room temperature for 6 h. The reaction mixture Was concentrated and the residue Was e1uted through an ion - exchange co1umn ( using methano1 and 7 N methano1 in ammonia ) to afford the desired product ( 13 mg , 32% ) as an offWhite so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 8.01 ( bs , 1H ) , 7.70 ( d , J=5.0 , Hz , 1H ) , 7.20 ( dd , J=5.0 , 4.0 Hz , 1H ) , 7.00 ( d , J=8.0 , Hz , 1H ) , 6.56 - 6.57 ( m , 1H ) , 3.70 - 3.05 ( m , 8H ) ; ES1 MS m / z 329 [ Cl6Hl6N4O2S + H ] + ; HPLC 95.5% ( AUC ) , tR=8.79 min. [ 0142 ] Genera1 Procedure B—Synthesis of Amides F as Described in Scheme ( 1 ) : . [ 0143 ] To a suspension of 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic acid ( 1.0 equiV ) in to1u - ene ( 5 - 15 mL ) Was added thiony1 ch10ride ( 4.0 equiV ) . After stirring at room temperature for 16 h , the reaction mixture Was heated at 70 degrees C. for 2 h. The reaction mixture Was coo1ed , and concentrated , and the residue Was suspended in THF ( 10 - 20 mL ) fo11oWed by the addition of pyridine ( 2.0 equiV ) and the corresponding amine ( 2.0 equiV ) and the reaction mixture Was heated at 70 degrees C. for 16 h. The reaction mixture Was concentrated and the residue Was di1uted With Water ( 20 mL ) and extracted With ethy1 acetate ( 3 x20 mL ) . The combined organic 1ayers Were Washed With satd. aq NaHCO3 ( 20 mL ) , concentrated , and puriﬁed by ﬂash chromatography ( si1ica , 0 - 15% methano1 / dich1oromethane ) to afford amides F. 1n most cases these intermediates Were iso - 18ted as crude products and Were carried forWard Without extensiVe characterization or further puriﬁcation. Examp1e 22. tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] piperidine - 1 - carboxy - 1ate. [ 0144 ] [ : ; : : T / ﬂ%c O NH N\ S NW ] H OCH3. Oct. 27 , 2011. [ 0145 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.15 g , 0.44 mmo1 ) Was reacted With racemic 3 - amino - 1 - boc - piperidne ( 0.18 g , 0.88 mmo1 ) to afford the desired product ( 0.13 g ) as a broWn so1id : ES1 MS m / z 443 [ C23H28N4O4S + H ] + . Examp1e 23. tert - Buty1 4 - { 2 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] ethy1 } piperazine - 1 - carboxy1ate. [ 0146 ] . Boc. [ 0147 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.16 g , 0.58 mmo1 ) Was reacted With tert - buty1 4 - ( 2 - aminoethy1 ) piperazine - 1 - carboxy1ate ( 0.27 g , 1.2 mmo1 ) to afford the desired product ( 0.24 g ) as a foam : ES1 MS m / z 486 [ C24H31N5O4S + H1 + - . O. ocH3. Examp1e 24. ( R ) - tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] piperidine - 1 - carboxy1ate. [ 0148 ] . OCH3. [ 0149 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.13 g , 0.46 mmo1 ) Was reacted With ( R ) - 3 - amino - 1 - boc - . Oct. 27 , 2011. US 2011 / 0263566 A1 25. piperidine ( 0.18 g , 0.92 mmo1 ) to afford the desired product Examp1e 27 ( 0.12 g ) as a broWn so1id : ES1 MS m / z 457 [ C23H28N4O4S + H ] + . tert - Buty1 4 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo. [ d ] imidazo1e - 4 - carboxamido ] piperidine - 1 - carboxy - . Examp1e 25 1ate [ 0154 ] . ( S ) - tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] piperidine - 1 - carboxy1ate. Boc. [ 0150 ] N Nj , Bm : [ : i ; : ] . [ : : ; : : J O NH. 0 NH N\ s §>—<\j ooH3. [ 0155 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid [ 0151 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( Q ' 16 g , 0°58 mmo1 ) WaS reacted W1th 4 - am1no - 1 - boc - p1per1 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid d1ne ( 0.23 g , .1.2 mmo1 ) to afford the des1red product ( 0.20 g ) ( 0.13 g , 0.46 mmo1 ) Was reacted With ( S ) - 3 - amino - 1 - boc - aS a broWn Oﬂ : ES1 MS m / z 457 [ C23H28N4O4S + H ] ' piperidine ( 0.18 g , 0.92 mmo1 ) to afford the desired product ( 0.13 g ) as a broWn oi1 : ES1 MS m / z 457 [ C23H28N4O4S + H ] + . Examp1e 28. OCH3. 7 - Methoxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 2 - ( thiophen - . Examp1e 26 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. tert - Buty1 3 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } piperidine - 1 - carboxy1ate. [ 0152 ] Q / CH3 H O NH O N\ / O\ , , , . OCH3. [ 0156 ] . oCH3. [ 0153 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - [ 01 , 57 ] Fo11oWing genera1 ' procedure B 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( th1ophen - 2 - y1 ) - 1H - benzo [ d ] 1m1dazo1e - 7 - carboxy11c ac1d ( 0.17 g , 0.62 mmo1 ) Was reacted With racemic 3 - aminom - ( 0 ' 16 g , 0 : 59 mmo1 ) WaS reacted W1th racem1c 1 - methy1 - . piperidin - 3 - amine ( 0.14 g , 1.2 mmo1 ) to afford the desired. ethy1 - 1 - boc - piperidine ( 0.26 g , 1.2 mmo1 ) to afford the desired product ( 0.23 g ) as a broWn oi1 : ES1 MS m / z 471 product ( 0.15 g ) as a br0WI1 g1ass : ES1 MS m / z 371. [ C24H3oN4O4S + H1 + - [ C1 9H22H4O2 S + H1 + - . US 2011 / 0263566 A1. 26. Examp1e 29. tert - Buty1 4 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } piperidine - 1 - carboxy1ate. [ 0158 ] . N / ch O§\ / © Ns W N\. ocH3. [ 0159 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.15 g , 0.56 mmo1 ) Was reacted With 4 - aminomethy1 - 1 - bocpiperidine ( 0.24 g , 1.1 mmo1 ) to afford the desired product ( 0.16 g ) as a broWn foam : ES1 MS m / z 471 [ C24H3ON4O4S + . H ] + . Examp1e 30. tert - Buty1 3 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } azetidine - 1 - carboxy1ate. [ 0160 ] . ocH3. [ 0161 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.15 g , 0.56 mmo1 ) Was reacted With 1 - boc - 3 ( aminomethy1 ) azetidine ( 0.20 g , 1.1 mmo1 ) to afford the desired product ( 0.17 g ) as a broWn foam : ES1 MS m / z 443 [ C22H26N4O4S + . H ] + . Oct. 27 , 2011. Examp1e 31. tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] pyrro1idine - 1 - carboxy - 1ate. [ 0162 ] . Bm. ooH3. [ 0163 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.15 g , 0.56 mmo1 ) Was reacted With 3 - amino - 1 - Boc - pyrro - 1idine ( 0.21 g , 1.1 mmo1 ) to afford the desired product ( 0.20 g ) as a broWn oi1 : ES1 MS m / z 443 [ C22H26N4O4S + H ] + . Examp1e 32. tert - Buty1 2 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } pip eridine - 1 - carboxy1ate. [ 0164 ] . OCH3. [ 0165 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.16 g , 0.58 mmo1 ) Was reacted With racemic 2 - ( aminomethy1 ) - 1 - N - boc - piperidine ( 0.25 g , 1.2 mmo1 ) to afford the desired product ( 0.23 g ) as a broWn foam : ES1 MS m / z 471. [ C24H3oN4O4S + H1 + - . US 2011 / 0263566 A1. Examp1e 33. tert - Buty1 3 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } pyrro1idine - 1 - carboxy1ate. [ 0166 ] . OCH3. [ 0167 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.16 g , 0.58 mmo1 ) Was reacted With 3 - ( aminomethy1 ) - 1 - N - Boc - pyrro1idine ( 0.24 g , 1.2 mmo1 ) to afford the desired product ( 0.19 g ) as a broWn oi1 : ES1 MS m / z 457 [ C23H28N4O4S + H1 + - . Examp1e 34. tert - Buty1 - 4 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] cyc1ohexy1carbamate. [ 0168 ] HN / ﬂ%c O NH N S m N \ OCH3. [ 0169 ] Fo11oWing genera1 procedure B , 4 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxy1ic acid ( 0.15 g , 0.55 mmo1 ) Was reacted With 1 - Boc - amino - 1 , 4 - cy - c1ohexy1diamine ( 0.23 g , 1.1 mmo1 ) to afford the desired product ( 92 mg ) as a broWn oi1 : ES1 MS m / z 471 [ C24H3oN4O4S + H1 + - . Genera1 Procedure C7Synthesis of Compounds as Described in Scheme ( 1 ) : . [ 0170 ] To a suspension of amides F ( 1.0 equiV ) in dich1o - roethane ( 10 - 25 mL ) Was added boron tribromide ( 6.0 - 10 equiV ) and the reaction mixture Was heated at 80 degrees C. for 16 h. The reaction mixture Was poured oVer ice and the resu1ting mixture Was concentrated. The crude residue Was. Oct. 27 , 2011. e1uted through an ion - exchange column ( using methano1 and 7 N methano1 in ammonia ) as a crude puriﬁcation. The crude product Was further puriﬁed by preparatiVe HPLC ( C1 8 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The desired product Was obtained as the triﬁuoroacetic acid sa1t Which Was e1uted through an ion - exchange co1umn ( using methano1 and 7 N methano1 in ammonia ) to obtain the desired products. Examp1e 35. 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0171 ] . OH. [ 0172 ] Fo11oWing genera1 procedure C , tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - car - . boxamido ] piperidine - 1 - carboxy1ate ( 0.13 g ) Was reacted With boron tribromide to afford the desired product ( 34 mg , 23% yie1d ) as a 11ght ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.86 - 7.85 ( m , 1H ) , 7.76 ( d , J : 8.4 Hz , 1H ) , 7.63 - 7.61 ( m , 1H ) , 7.22 - 7.19 ( m , 1H ) , 6.66 ( d , J=8.4 Hz , 1H ) , 4.14 - 4.10 ( m , 1H ) , 3.04 - 3.00 ( m , 1H ) , 2.86 - 2.77 ( m , 2H ) , 2.18 - 1.99 ( m , 2H ) , 1.79 - 1.72 ( m , 2H ) ; ES1 MS m / z 343 [ Cl7Hl8N4O2S + H ] + ; HPLC 99.2% ( AUC ) , tR : 9.73 min. Examp1e 36. 7 - Hydroxy - N - [ 2 - ( piperazin - 1 - y1 ) ethy1 ] - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0173 ] E. O U. [ 0174 ] Fo11oWing genera1 procedure C , tert - Buty1 [ 0175 ] 4 - { 2 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] ethy1 } piperazine - 1 - carboxy1ate. O. OH. US 2011 / 0263566 A1. ( 0.24 g ) Was reacted With boron tribromide to afford the desired product ( 70 mg , 32% yie1d ) as a White so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 9.50 ( s , 1H ) , 8.08 ( d , J : 2.0 Hz , 1H ) , 7.77 ( d , J=5.0 Hz , 1H ) , 7.69 ( d , J=8.0 Hz , 1H ) , 7.25 - 7.24 ( m , 1H ) , 6.71 ( d , J : 8.0 Hz , 1H ) , 3.55 - 3.51 ( m , 3H ) , 2.90 - 2.84 ( m , 5H ) , 2.56 - 2.50 ( m , 3H ) ; ES1 MS m / z 372 [ Cl8H21N5O2S + H ] + ; HPLC >99% ( AUC ) , tR : 8.74 min. Examp1e 37. ( R ) - 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0176 ] . OH. [ 0177 ] Fo11oWing genera1 procedure C , ( R ) - tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] piperidine - 1 - carboxy1ate ( 0.12 g ) Was reacted With boron tribromide to afford the desired product ( 25 mg , 16% yie1d ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.88 - 7.87 ( m , 1H ) , 7.79 - 7.75 ( m , 1H ) , 7.65 - 7. 63 ( m , 1H ) , 7.24 - 7.21 ( m , 1H ) , 6.70 - 6.67 ( m , 1H ) , 4.17 - 4.14 ( m , 1H ) , 3.08 - 3.00 ( m , 1H ) , 2.89 - 2.78 ( m , 2H ) , 2.24 - 1.98 ( m , 2H ) , 1.82 - 1.76 ( m , 2H ) ; ES1 MS m / z 343 [ Cl7Hl8N4O2S + H ] + ; HPLC 96.1% ( AUC ) , tR : 10.50 min. Examp1e 38. ( S ) - 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0178 ] . NH. [ 0179 ] Fo11oWing genera1 procedure C , ( S ) - tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] piperidine - 1 - carboxy1ate ( 0.13 g ) Was reacted. OH. Oct. 27 , 2011. With boron tribromide to afford the desired product ( 45 mg , 29% yie1d ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.88 - 7.87 ( m , 1H ) , 7.79 - 7.75 ( m , 1H ) , 7.65 - 7. 63 ( m , 1H ) , 7.24 - 7.21 ( m , 1H ) , 6.70 - 6.66 ( m , 1H ) , 4.17 - 4.14 ( m , 1H ) , 3.08 - 3.00 ( m , 1H ) , 2.89 - 2.78 ( m , 2H ) , 2.24 - 1.98 ( m , 2H ) , 1.82 - 1.76 ( m , 2H ) ; ES1 MS m / z 343 [ Cl7H18N4O2S + H ] + ; HPLC >99% ( AUC ) , tR : 9.80 min. Examp1e 3 9. 7 - Hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0180 ] . OH. [ 0181 ] Fo11oWing genera1 procedure C , tert - Buty1 3 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } piperidine - 1 - carboxy1ate ( 0.23 g ) Was reacted With boron tribromide to afford the desired product ( 90 mg , 41% yie1d ) as a 1ight broWn so1id : 1H NMR ( 300 MHz , DMSO - d6 ) de1ta 9.62 ( s , 1H ) , 8.06 - 8.04 ( m , 1H ) , 7.74 ( d , J=4.8 Hz , 1H ) , 7.64 ( d , J=8.4 Hz , 1H ) , 7.24 - 7.21 ( m , 1H ) , 6.66 ( d , J=8.4 Hz , 1H ) , 3.29 ( t , J=6.0 Hz , 2H ) , 3.17 - 3.10 ( m , 1H ) , 2.93 - 2.89 ( m , 1H ) , 2.47 - 2.37 ( m , 2H ) , 1.95 - 1.90 ( m , 1H ) , 1.76 - 1.63 ( m , 2H ) , 1.49 - 1.20 ( m , 2H ) ; ES1 MS m / z 357 [ Cl8H2ON4O2S + H ] + ; HPLC >99% ( AUC ) , tR : 9.41 min. Examp1e 40. 7 - Hydroxy - N - ( piperidin - 4 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0182 ] . ZZ. . HJ. [ 0183 ] Fo11oWing genera1 procedure C , tert - Buty1 4 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - car - . boxamido ] piperidine - 1 - carboxy1ate ( 02 g ) Was reacted With boron tribromide to afford the desired product ( 85 mg , 42%. OH. US 2011 / 0263566 A1. yie1d ) as a 11ght ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.85 - 7.84 ( m , 1H ) , 7.76 ( d , J : 5.1 Hz , 1H ) , 7.62 - 7.6O ( m , 1H ) , 7.21 - 7.19 ( m , 1H ) , 6.66 ( d , J : 5.1 Hz , 1H ) , 4.21 - 4.20 ( m , 1H ) , 3.29 - 3.24 ( m , 2H ) , 2.99 - 2.93 ( m , 2H ) , 2.17 - 2.14 ( m , 2H ) , 1.80 - 1.74 ( m , 2H ) ; ES1 MS m / z 343 [ Cl7Hl8N4O2S + H ] + ; HPLC >99% ( AUC ) , tR=9.07 min. Examp1e 41. 7 - Hydroxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0184 ] . CH3. [ 0185 ] Fo11oWing genera1 procedure C , 7 - methoxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imida - zo1e - 4 - carboxamide ( 0.15 g ) Was reacted With boron tribromide to afford the desired product ( 75 mg , 36% yie1d ) as a 11ght ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.89 - 7.88 ( m , 1H ) , 7.78 ( d , J=8.4 Hz , 1H ) , 7.65 - 7.64 ( m , 1H ) , 7.23 - 7.20 ( m , 1H ) , 6.71 ( d , J : 8.4 Hz , 1H ) , 4.26 - 4.24 ( m , 1H ) , 3.01 - 2.98 ( m , 1H ) , 2.67 - 2.65 ( m , 1H ) , 2.38 ( s , 5H ) , 2.05 - 1.92 ( m , 2H ) , 1.80 - 1.59 ( m , 2H ) ; ES1 MS m / z 357 [ Cl8H20N4O2S + H ] + ; HPLC 96.2% ( AUC ) , tR=9.55 min. OH. Examp1e 42. 7 - Hydroxy - N - ( piperidin - 4 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0186 ] . OH. [ 0187 ] Fo11oWing genera1 procedure C , tert - Buty1 4 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - car - . boxamido ] methy1 } piperidine - 1 - carboxy1ate ( 0.16 g ) Was reacted With boron tribromide to afford the desired product ( 700 mg , 35% yie1d ) as a ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.85 - 7.84 ( m , 1H ) , 7.78 - 7.74 ( m , 1H ) , 7.63 - 7. 61 ( m , 1H ) , 7.23 - 7.19 ( m , 1H ) , 6.64 - 6.61 ( m , 1H ) , 3.49 ( d , . Oct. 27 , 2011. J : 6.6 Hz , 2H ) , 2.88—2.79 ( m , 2H ) , 2.07—2.03 ( m , 2H ) , 1.94— 1.93 ( m , 1H ) , 1.56 - 1.44 ( m , 2H ) ; ESI Ms m / z 357 [ C , 8H2ON4O2S + H ] + ; HPLC >999 / 0 ( AUC ) , t , : 9.15 min. Examp1e 43. N - ( Azetidin - 3 - y1methy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0188 ] . NH N\ S , MJ. [ 0189 ] Fo11oWing genera1 procedure C , tert - Buty1 3 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } azetidine - 1 - carboxy1ate ( 0.17 g ) Was reacted With boron tribromide to afford the desired product ( 43 mg , 24% yie1d ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.84 - 7.83 ( m , 1H ) , 7.74 ( d , J : 8.4 Hz , 1H ) , 7.62 - 7.59 ( m , 1H ) , 7.22 - 7.19 ( m , 1H ) , 6.61 ( d , J=8.4 Hz , 1H ) , 4.02 - 3.96 ( m , 2H ) , 3.90 - 2.84 ( m , 2H ) , 3.74 ( d , J=6.3 Hz , 2H ) ; ES1 MS m / z 329 [ C16Hl6N4O2S + H ] + ; HPLC >99% ( AUC ) , tR=8.70 min. OH. Examp1e 44. 7 - Hydroxy - N - ( pyrro1idin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0190 ] . [ 0191 ] Fo11oWing genera1 procedure C , tert - Buty1 3 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - car - . boxamido ] pyrrohdine - l - carboxy1ate ( 0.20 g ) Was reacted With boron tribromide to afford the desired product ( 0.12 g , 63% yie1d ) as a 11ght broWn so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 8.09 ( s , 1H ) , 7.90 ( d , J : 8.4 Hz , 2H ) , 7.36 - 7.33 ( m , 1H ) , 6.87 ( d , J : 8.4 Hz , 1H ) , 4.75 - 4.71 ( m , 1H ) , 3.69 - 3.64. OH. US 2011 / 0263566 A1. ( m , 2H ) , 3.54—3.48 ( m , 2H ) , 2.54—2.50 ( m , 1H ) , 2.35—2.30 ( m , 1H ) ; ES1 Ms m / z 329 [ C , 6H , 6N4O2S + H ] + ; HPLC >99% ( AUC ) , t , : 8.80 min. Examp1e 45. 7 - Hydroxy - N - ( piperidin - 2 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0192 ] . OH. [ 0193 ] Fo11oWing genera1 procedure C , tert - Buty1 2 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } piperidine - 1 - carboxy1ate ( 0.23 g ) Was reacted With boron tribromide to afford the desired product ( 90 mg , 44% yie1d ) as a ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 8.03 - 8.02 ( m , 1H ) , 7.87 ( d , J=8.4. [ 0194 ] Hz , 1H ) , 7.82 - 7.81 ( m , 1H ) , 7.32 - 7.29 ( m , 1H ) , 6.83 ( d , J : 8.4 Hz , 1H ) , 3.78 - 3.75 ( m , 2H ) , 3.44 - 3.36 ( m , 2H ) , 3.06 - 3.02 ( m , 1H ) , 2.14 - 2.10 ( m , 1H ) , 2.00 - 1.90 ( m , 2H ) , 1.75 - 1.66 ( m , 3H ) ; ES1 MS m / z 357 [ Cl8H20N4O2S + H ] + ; HPLC >99% ( AUC ) , tR : 9.49 min. Examp1e 46. 7 - Hydroxy - N - ( pyrro1idin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. 0 EvCNH N S HE H. [ 0196 ] Fo11oWing genera1 procedure C , tert - Buty1 3 - { [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - car - . boxamido ] methy1 } pyrro1idine - 1 - carboxy1ate ( 0.19 g ) Was reacted With boron tribromide to afford the desired product ( 79 mg , 39% yie1d ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.84 - 7.82 ( m , 1H ) , 7.75 ( d , J : 8.4 Hz , 1H ) , 7.61 - 7.59 ( m , 1H ) , 7.21 - 7.18 ( m , 1H ) , 6.61 ( d , J : 8.4 Hz , 1H ) , 3.63 - 3.54 ( m , 2H ) , 3.37 - 3.33 ( m , 1H ) , 3.27 - 3.06 ( m , 2H ) , 2.98 - 2.91 ( m , 1H ) , 2.66 - 2.61 ( m , 1H ) , 2.24 - 2.18 ( m , . [ 0195 ] . OH. Oct. 27 , 2011. 1H ) , 1.86 - 1.79 ( m , 1H ) ; ES1 Ms m / z 343 [ Cl7H , 8N , O2S + H ] + ; HPLC >99% ( AUC ) , t , : 8.91 min. Examp1e 47. N - ( 4 - Aminocyc1ohexy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0197 ] 5 0 EH N\ S fO OH. [ 0198 ] Fo11oWing genera1 procedure C , tert - Buty1 - 4 - [ 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] cyc1ohexy1carbamate ( 92 mg ) Was reacted With boron tribromide to afford the desired product ( 21 mg , 10% yie1d oVer tWo steps ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.85 - 7.84 ( m , 1H ) , 7.77 ( d , J : 8.4 Hz , 1H ) , 7.61 - 7.59 ( m , 1H ) , 7.22 - 7.17 ( m , 1H ) , 6.63 ( d , J=8.4 Hz , 1H ) , 4.24 - 4.23 ( m , 1H ) , 3.01 - 2.97 ( m , 1H ) , 2.15 - 2.10 ( m , 2H ) , 2.03 - 1.78 ( m , 6H ) ; ES1 MS m / z 357 [ Cl8H2ON4O2S + H ] + ; HPLC 95.6% ( AUC ) , tR : 9.22 min. Examp1e 48. 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0199 ] . OH. [ 0200 ] Fo11oWing Genera1 Procedure C , tert - Buty1 3 - ( ( 2 - ( bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imida - . zo1e - 4 - carboxamido ) methy1 ) piperidine - 1 - carboxy1ate ( 330 mg crude ) Was reacted With boron tribromide to afford the desired product ( 71 mg , 45% yie1d ) as a 11ghtye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.75 - 7.68 ( m , 1H ) , 6.58 ( dd , 1H , J : 4.0 , 8.2 Hz ) , 3.47 - 3.36 ( m , 2H ) , 3.27 - 3.20 ( m , 1H ) , 3.11 - 3.05 ( m , 1H ) , 3.01 - 2.96 ( m , 1H , minor diastereomer ) , . US 2011 / 0263566 A1. 2.69 - 2.62 ( m , 1H ) , 2.57 - 2.51 ( m 1H ) , 2.43 - 2.37 ( m , 1H ) , 2.25 - 2.19 ( m , 1H , minor diastereomer ) , 2.09 - 2.01 ( m , 2H ) , 1.96 - 1.88 ( m , 1H ) , 1.84 - 1.74 ( m , 2H ) , 1.71 - 1.55 ( m , 3H ) , 1.53 - 1.16 ( m , 5H ) ; ES1 MS m / z 369 [ C2lH28N4O2 + H ] + ; HPLC >99% ( AUC ) , tR=9.75 min. Examp1e 49. 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0201 ] . OH. [ 0202 ] Fo11oWing Genera1 Procedure C , tent - Buty1 3 - ( 2 - ( bicyc1o [ 2.2. 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imida - zo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate ( 210 mg crude ) Was reacted With boron tribromide to afford the desired product ( 72 mg , 43% yie1d ) as a 11ght ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.69 ( dd , J : 3.6 , 8.1 Hz , 1H ) , 6.61 ( dd , J=2.7 , 8.1 Hz , 1H ) , 4.12 - 4.01 ( m , 1H ) , 3.45 - 3.36 ( m , 1H ) , 3.03 - 2.93 ( m , 1H ) , 2.78 - 2.52 ( m , 3H ) , 2.44 - 2.36 ( m , 1H ) , 2.25 - 1.16 ( m 13H ) ; ES1 MS m / z 355 [ C2OH26N4O2 H ] + ; HPLC >99% ( AUC ) , t R : 9.55 min ( minor diastereomer ) , 9.74 min ( major diastereomer ) . Genera1 Procedure D—Synthesis of Compounds of Formu1a ( 1 - 11 ) as Described in Scheme ( 1 ) : . [ 0203 ] To a so1ution of acid ( 1 .0 equiV ) in DMF ( 5 - 10 mL ) Was added HATU ( 1.2 - 1.5 equiV ) , D1PEA ( 3.0 - 5.0 equiV ) , and the amine ( 1 .5 - 2.0 equiV ) and the reaction mixture Was either stirred at room temperature for 16 h or heated at 50 - 70 degrees C. for 16 h. The reaction mixture Was di1uted With satd. aq NaHCO3 ( 20 mL ) and extracted With ethy1 acetate ( 3x20 mL ) . The combined organic 1ayer Was dried oVer Na2SO4 , concentrated , and puriﬁed by preparatiVe HPLC ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The desired product Was obtained as the triﬁuoroacetic acid sa1t Which Was e1uted through an ion - exchange column ( using methano1 and 7 N methano1 in ammonia ) to obtain the desired products. 1n some instances , the desired product Was treated With TFA ( 1 - 2 mL ) for 1 h , concentrated and puriﬁed by preparatiVe HPLC. [ 0204 ] ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The desired product Was obtained as the triﬁuoroacetic acid sa1t Which Was e1uted through an ion - exchange co1umn ( using methano1 and 7 N methano1 in ammonia ) to obtain the desired products. Oct. 27 , 2011. Examp1e 50. ( S ) - tert - Buty1 3 - ( 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate. [ 0205 ] . OH. [ 0206 ] Fo11oWing Genera1 Procedure D , 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic acid ( 90 mg , 0.27 mmo1 ) Was reacted With ( S ) - tertbuty13 - aminopiperidine - 1 - carboxy1ate ( 106 mg , 0.53 mmo1 ) to afford the desired product ( 48 mg , 35% yie1d ) as ye11oWbroWn so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.84 ( d , J=8.5 Hz , 1H ) , 7.71 ( s , 1H ) , 7.28 ( s , 1H ) , 6.78 ( d , J=8.5 Hz , 1H ) , 4.21 ( bs , 1H ) , 3.86 ( bs , 1H ) , 3.58 - 3.18 m , 2H ) , 2.14 - 2.03 ( m , 2H ) , 1.89 ( bs , 1H ) , 1.59 ( bs , 1H ) , 1.17 ( bs , 1H ) ; ES1 MS m / z 521 [ C22H25BrN4O4S ] + ; HPLC >99% ( AUC ) , tR=15.30 m1n. Examp1e 51. ( S ) - 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0207 ] . NH O NH N W E S Br. OH. [ 0208 ] A so1ution of ( S ) - tert - buty1 3 - ( 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) pi - . peridine - 1 - carboxy1ate ( 35 mg , 0.067 mmo1 ) in CH2C12 ( 1 mL ) and TFA ( 1 mL ) Was stirred at room temperature for 1 h. The reaction mixture Was concentrated and puriﬁed by puri - ﬁed by preparatiVe HPLC ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The desired product Was obtained as the triﬁuoroacetic acid sa1t Which Was e1uted through an ionexchange co1umn ( using methano1 and 7 N methano1 in. US 2011 / 0263566 A1. ammonia ) to obtain the desired ( 20 mg , 72% ) as ye11oW so1id : 1H NMR ( 500 MHz , DMSO - d6 ) de1ta 13.61 ( s , 1H ) , 11.00 ( s , 1H ) , 9.57 ( d , J : 6.5 Hz , 1H ) , 8.75 ( bs , 1H ) , 7.89 ( d , J : 4.0 Hz , 1H ) , 7.72 ( d , J=8.0 Hz , 1H ) , 7.41 ( d , J=3.5 Hz , 1H ) , 6.77 ( d , J : 8.5 Hz , 1H ) , 3.46 ( d , J : 8.5 Hz , 1H ) , 3.21 ( d , J : 12.5 Hz , 1H ) , 3.04 - 2.96 ( m , 2H ) , 2.1O ( bs , 1H ) , 2.03 - 2.00 ( m , 2H ) , 1.85 - 1.70 ( m , 4H ) , 0.68 ( bs , 1H ) ; ES1 MS m / z 421 [ C , 7H , 7BrN4O2S ] + ; HPLC 98.34% ( AUC ) , tR : 8.17 min. Examp1e 52. 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( ( S ) - piperidin - 3 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0209 ] . OH. [ 0210 ] Fo11oWing Genera1 Procedure C , ( 3S ) - tert - Buty1 3 - ( 2 - ( bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate ( 230 mg , crude ) Was reacted With boron tribromide to afford the desired product ( 103 mg , 52% oVer tWo steps ) as a 1ight broWn so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.69 ( dd , J : 3.6 , 8.4 Hz , 1H ) , 6.60 ( dd , J=2.7 , 8.4 Hz , 1H ) , 4.12 - 4.02 ( m , 1H ) , 3.46 - 3.35 ( m , 1H ) , 3.03 - 2.93 ( m , 1H ) , 2.78 - 2.60 ( m , 3H ) , 2.56 - 2.36 ( m , 1H ) , 2.25 - 1.17 ( m , 13H ) ; ES1 MS m / z 355 [ C2OH26N4O2 + H ] + ; HPLC 99.0% ( AUC ) , tR=9.35 min ( minor diastereomer ) , 9.49 min ( major diastereomer ) . Examp1e 53. 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( adamantane - 3 - y1amino ) - 1H - benzo [ d ] imidazo1e - 4 - car - . boxamide [ 0211 ] H , N % O NH. OH. [ 0212 ] Fo11oWing Genera1 Procedure C , tert - Buty1 3 - { [ 2 - ( bicyc1o [ 2.2. 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imida - zo1e - 4 - carboxamido ] methy1 } adamantane - 1 - carboxy1ate. Oct. 27 , 2011. ( 140 mg , crude ) Was reacted With boron tribromide to afford the desired product ( 57 mg , 31% oVer tWo steps ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.66 - 7.62 ( m , 1H ) , 6.57 - 6.53 ( m , 1H ) , 3.45 - 3.35 ( m , 1H ) , 3.00 - 2.90 ( m , 1H , minor diastereomer ) , 2.68 - 2.62 ( m , 1H , major diastereomer ) , 2.56 - 2.52 ( m , 1H , minor diastereomer ) , 2.43 - 2.18 ( m , 7H ) , 2.13 - 1.99 ( m 3H ) , 1.84 - 1.21 ( m , 12H ) ; ES1 MS m / z 421 [ C25H32N4O2 + H ] + ; HPLC 96.6% ( AUC ) , tR : 1045 min. Examp1e 54. 2 - ( Thiophene - 2 - y1 ) - 7 - hydroxy - N - ( adamantate - 3 - y1amino ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0213 ] . OH. [ 0214 ] Fo11oWing Genera1 Procedure C , tert - Buty1 3 - ( ( 2 - thiophene - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) methy1 ) adamantane - 1 - carboxy1ate ( 110 mg ) Was reacted With boron tribromide to afford the desired product ( 62 mg , 28% oVer tWo steps ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.80 ( d , J : 3.9 Hz , 1H ) , 7.69 ( d , J=8.4 Hz , 1H ) , 7.58 ( d , 4.8 Hz ) , 7.20 - 7.17 ( m , 1H ) , 6.59 ( d , 1H , J : 8.4 Hz ) , 2.38 - 2.11 ( m , 8H ) , 1.86 - 1.63 ( m , 6H ) ; ES1MS m / z 409 [ C22H24N4O2S + H ] + ; HPLC >99% ( AUC ) , tR : 11.27 m1n. Examp1e 55. N - ( 3 - Aminocyc1ohexy1 ) - 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0215 ] . OH. [ 0216 ] Fo11oWing Genera1 Procedure C , tert - Buty1 3 - ( 2 - ( bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imida - . zo1e - 4 - carboxamido ) cyc1ohexy1carbamate ( 120 mg , crude ) Was reacted With boron tribromide to afford the desired prod - . uct ( 66 mg , 40% yie1d ) as a 1ight ye11oW so1id : 1H NMR ( 300. US 2011 / 0263566 A1. MHz , CD3OD ) de1ta 7.72 - 7.67 ( m , 1H ) , 6.58 - 6.55 ( m , 1H ) , 4.57 - 4.48 ( m , 1H , minor diastereomer ) , 4.03 - 3.90 ( m , 1H , major diastereomer ) , 3.45 - 3.35 ( m , 1H ) , 3.03 - 2.90 ( m , 1H ) , 2.66 - 2.52 ( m , 1H ) , 2.44 - 2.32 ( m 2H , major diastereomer ) , 2.22 - 1.14 ( m , 15H ) ; ES1 MS m / z 369 [ C2lH28N4O2 + H ] + ; HPLC >99% ( AUC ) , tR=9.40 , 9.53 , 9.58 , 9.81 min ( mixture of diastereomers ) . Examp1e 56. N - { [ ( cis ) - 4 - Aminocyc1ohexy1 ] methy1 } - 2 - ( bicyc1o [ 2. 2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. NH2 111 O N. N. \. N H. [ 0217 ] . . . OH. [ 0218 ] Fo11oWing Genera1 Procedure C , tert - Buty1 ( cis ) - 4 - { [ 2 - ( bicyc1o [ 2 .2 . 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy 1 } cyc1ohexy1carbamate ( 220 mg crude ) Was reacted With boron tribromide to afford the desired product ( 64 mg , 53% oVer tWo steps ) as a 1ight ye11oW so1id : 1H NMR ( 300 MHz , CD3OD ) de1ta 7.69 ( dd , J : 3.9 , 8.4 Hz , 1H ) , 6.59 - 6.54 ( m , 1H ) , 3.56 - 3.37 ( m , 2H ) , 3.15 - 3.07 ( m , 1H ) , 3.00 - 2.90 ( m , 1H , minor diastereomer ) , 2.74 - 2.66 ( m , 1H , minor diastereomer ) , 2.55 - 2.51 ( m , 1H , minor diastereomer ) , 2.42 - 2.34 ( m , 1H ) , 2.25 - 2.16 ( m , 1H , minor diastereomer ) , 2.06 - 1.98 ( m , 1H ) , 1.80 - 1.20 ( m , 14H ) ; ES1 MS m / z 383 [ C22H30N4O2 + H ] + ; HPLC 99.0% ( AUC ) , tR=9.53 , 9.88 , 9.96 min ( mixture of diastereomers ) . Examp1e 57. ( S ) - 7 - hydroxy - 2 - ( 5 - ( piperazin - 1 - y1 ) thiophen - 2 - y1 ) - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0219 ] . mz / 21 3. NH. Oct. 27 , 2011. [ 0220 ] A mixture of ( S ) - tert - Buty1 3 - ( 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate ( 0.12 g , 0.24 mmo1 ) , tert - buty1 piperazine - 1 - carboxy1ate ( 110 mg , 0.60 mmo1 ) , Cu1 ( 5.7 mg , 0O30 mmo1 ) , Cu ( 2.0 mg , 0.030 mmo1 ) , K3PO4. H2O ( 160 mg , 0.72 mmo1 ) in 2 - ( dimethy1amino ) ethano1 ( 2 mL ) Was stirred at 75 degrees C. for 18 h. The reaction mixture Was coo1ed , concentrated , disso1Ved in CH3OH ( 3 mL ) and ﬁ1 - tered. The ﬁ1trate Was puriﬁed by preparatiVe HPLC ( C18 si1ica , 10 - 90% acetonitri1e / Water With 0.05% TFA ) . The desired fractions Were combined , concentrated and the residue Was disso1Ved in CH2C12 ( 2 mL ) and TFA ( 1 mL ) and stirred at rt for 30 min. The reaction mixture Was concentrated and the residue Was e1uted through an ion - exchange co1umn ( SCX - 2 ) ( using methano1 and 7 N methano1 in ammonia ) to obtain the desired product ( 7 mg , 14% yie1d ) as a ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 8.20 ( d , J=4.5 Hz , 1H ) , 7.50 ( d , J=4.5 Hz , 1H ) , 7.14 ( d , J=4.0 Hz , 1H ) , 6.54 ( d , J=3.5 Hz , 1H ) , 4.20 - 4.16 ( m , 1H ) , 3.43 ( dd , J=12.5 , 3.5 Hz , 1H ) , 3.19 - 3.15 ( m , 2H ) , 3.10 - 2.97 ( m , 3H ) , 2.05 - 1.96 ( m , 2H ) , 1.84 - 1.72 ( m , 3H ) , 1.19 - 1.16 ( m , 1H ) , 1.13 - 1.08 ( m , 1H ) ; ES1 MS m / z 427 [ C2lH26N6O2S + H ] + HPLC 97.13% ( AUC ) , tR=8.29 min. Examp1e 58. ( R ) - 7 - hydroxy - N - ( pipe1idin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0221 ] . OH. mz / Z 4. [ 0222 ] Fo11oWing Genera1 Procedure D , 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic acid ( 0.13 mg , 0.47 mmo1 ) Was reacted With ( S ) - tertbuty1 3 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 200 mg , 093 mmo1 ) and the intermediate Was treated With TFA to afford the desired product ( 15 mg , 31 % yie1d ) as ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.75 ( d , J : 8.5 Hz , 1H ) , 7.30 ( dd , J=5.5 , 1.5 Hz , 1H ) , 7.02 - 7.01 ( m , 1H ) , 6.98 ( dd , J=5.0 , 3.5 Hz , 1H ) , 6.70 ( d , J=8.5 Hz , 1H ) , 4.52 ( s , 2H ) , 3.53 - 3.45 ( m , 2H ) , 3.37 ( dd , J : 9.0 , 6.0 Hz , 1H ) , 2.95 - 2.89 ( m , 2H ) , 2.82 ( t , J=12.0 Hz , 1H ) , 2.15 - 2.11 ( m , 1H ) , 2.00 - 1.94 ( m , 3H ) , 1.78 - 1.74 ( m , 1H ) , 1.44 - 1.36 ( m , 2H ) ; ES1 MS m / z 371 [ C19H22N4O2S + H ] + HPLC 95.5% ( AUC ) , tR : 7.17 min. US 2011 / 0263566 A1. Examp1e 59. ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0223 ] 9. O NH. mz / 21 8. oH S / . [ 0224 ] Fo11oWing Genera1 Procedure D , 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - car - . boxy1ic acid ( 0.17 mg , 0.62 mmo1 ) Was reacted With ( S ) - tertbuty1 3 - aminopiperidine - 1 - carboxy1ate ( 250 mg , 1.3 mmo1 ) and the intermediate Was treated With TFA to afford the desired product ( 25 mg , 68% yie1d ) as ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.63 ( d , J=8.5 Hz , 1H ) , 7.20 ( dd , J=5.0 , 1.0 Hz , 1H ) , 6.91 ( dd , J=5.0 , 3.5 Hz , 1H ) , 6.57 ( d , J=8.5 Hz , 1H ) , 4.37 ( s , 2H ) , 4.15 - 4.11 ( m , 1H ) , 3.37 ( dd , J=10.5 , 3.5 Hz , 1H ) , 3.14 - 3.11 ( m , 1H ) , 2.93 - 2.86 ( m , 2H ) , 2.04 - 2.01 ( m , 1H ) , 1.94 - 1.91 ( m , 1H ) , 1.74 - 1.65 ( m , 2H ) . ES1 MS m / z 357 [ Cl8H20N4O2S + H ] + HPLC 96.59% ( AUC ) , tR : 7.07 min. Examp1e 60. ( S ) - 7 - hydroxy - N - ( pipe1idin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. [ 0225 ] . mz / Z J b. oH S / . [ 0226 ] Fo11oWing Genera1 Procedure D , 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic acid ( 0.13 mg , 0.47 mmo1 ) Was reacted With ( R ) - tertbuty1 3 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 200 mg , 0.93 mmo1 ) and the intermediate Was treated With TFA to afford the desired product ( 12 mg , 28% yie1d ) as ye11oW so1id : 1H NMR ( 500 MHz , CD3OD ) de1ta 7.75 ( d , J : 8.5 Hz , 1H ) , 7.30 ( dd , J : 5.5 , 1.5 Hz , 1H ) , 7.02 - 7.01 ( m , 1H ) , 6.98 ( dd , J : 5.0 , 3.5 Hz , 1H ) , 6.70 ( d , J : 5.0 Hz , 1H ) , 4.50 ( s , 2H ) , 3.51 - 3.48 ( m , 2H ) , 3.37 ( dd , J : 13.0 , 7.0 Hz , 1H ) , 2.92 - 2.89. Oct. 27 , 2011. ( m , 2H ) , 2.80 ( t , J : 12.0 Hz , 1H ) , 2.16 - 2.10 ( m , 1H ) , 2.00 - 1. 95 ( m , 3H ) , 1.80 - 1.72 ( m , 1H ) , 1.44—1.39 ( m , 2H ) ; ES1 Ms m / z 371 [ C , 9H , 2N4O2S + H ] + HPLC 96.8% ( AUC ) , t , : 6.93 111111. Examp1e 61. Step 1 : Synthesis of Methy1 3 - ( 5 - bromothiophene - 2 - carboximidamido ) - 4 - methoxybenzoate Hydroch10 - ride. [ 0227 ] . o ocH3. ' HC1 NH. S E l Br OCH3 / . [ 0228 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 3 - amino - 4 - methoxybenzoate ( 1.5 g , 7.9 mmo1 ) Was reacted With 5 - bromothiophene - 2 - carbonitri1e ( 3.0 g , 16 mmo1 ) to afford the desired product ( 1.6 g , 54% yie1d ) as a dark broWn so1id : ES1 MS m / z 368 [ Cl4Hl3BrN2O3S + H ] + . Step 2 : Synthesis of Methy1 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate [ 0229 ] . OCH3. [ 0230 ] Fo11oWing the procedure out1ined for step 2 in Examp1e 1 , methy1 3 - ( 5 - bromothiophene - 2 - carboximidamido ) - 4 - methoxybenzoate hydroch1oride ( 1.7 g , 4.2 mmo1 ) Was reacted With 5% aq NaOC1 and satd. aq NaHCO3 to. afford the desired product ( 0.45 g , 30% yie1d ) as a broWn so1id : ES1 MS m / z 369 [ C14Hl1BrN2O3S + H ] + . Step 3 : Synthesis of 2 - ( 5 - Bromothiophen - 2 - y1 ) - 7 - hydroxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0231 ] . OH. US 2011 / 0263566 A1. [ 0232 ] Fo11oWing the procedure out1ined for step 4 in Examp1e 1 , methy1 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate ( 0.40 g , 1.1 mmo1 ) Was reacted With boron tribromide ( 1.5 g , 6.6 mmo1 ) to afford the desired product ( 0.34 g , 92% yie1d ) as a 1ight broWn so1id : ES1 MS m / z 340 [ Cl2H7BrN2O3S + H ] + . Examp1e 62. Step 1 : Synthesis of Methy1 4 - methoxy - 3 - ( 2 - ( thiophen - 2 - y1 ) acetimidamido ) benzoate Hydroch1o - ride [ 0233 ] . o ocH3. - Hc1 NH 8 \ N H ooH3. [ 0234 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 3 - amino - 4 - methoxybenzoate ( 2.2 g , 12 mmo1 ) Was reacted With 2 - ( thiophen - 2 - y1 ) acetonitri1e ( 3.0 g , 24 mmo1 ) to afford the desired product ( 3.2 g , 78% yie1d ) as a ye11oW broWn so1id : ES1 MS m / z 305 [ Cl5Hl6N2O3S + H ] + . Step 2 : Synthesis of Methy1 7 - methoxy - 2 - ( thiophen - 2 - y1methy1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxy1ate. [ 0235 ] o oCH3 A f. ocH3. mz / Z. [ 023 6 ] Fo11oWing the procedure out1ined for step 2 in Examp1e 1 , methy1 4 - methoxy - 3 - ( 2 - ( thiophen - 2 - y1 ) acetimidamido ) benzoate hydroch1oride ( 3. 1 g , 10 mmo1 ) Was reacted With 5% aq NaOC1 and satd. aq NaHCO3 to afford the desired product ( 1.1 g , 30% yie1d ) as a broWn so1id : ES1 MS m / z 303 [ C15H14N2O3S + H1 + - . Step 3 : Synthesis of 7 - hydroxy - 2 - ( thiophen - 2 - y1m - ethy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0237 ] . 16. OH. [ 0238 ] Fo11oWing the procedure out1ined for step 4 in Examp1e 1 , methy1 7 - methoxy - 2 - ( thiophene - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate ( 0.91 g , 3.0 mmo1 ) Was. Oct. 27 , 2011. reacted With boron tribromide ( 4.5 g , 18 mmo1 ) to afford the desired product ( 063 g , 73% yie1d ) as a 1ight broWn so1id : ES1 MS m / z 275 [ C13H1ON2O3S + H ] + . Examp1e 63. Step 1 : Synthesis of Methy1 3 - ( bicyc1o [ 2.2.1 ] heptane - 2 - carboximidamido ) - 4 - methoxybenzoate. [ 0239 ] . O OCH3. ' HC1 NH. N H. . . OCH3. [ 0240 ] Fo11oWing the procedure out1ined for step 1 in Examp1e 1 , methy1 - 3 - amino - 4 - methoxy benzoate ( 7.5 g , 41 mmo1 ) Was reacted With 2 - norbomane carbonitri1e ( 10 g , 82 mmo1 ) to afford product ( 11 g , 90% ) as a White so1id : 1H NMR ( 300 MHz , DMSO - d6 ) de1ta 8.29 - 8.20 ( m , 1H ) , 7.99 - 7.96 ( m , 1H ) , 7.33 - 7.28 ( m , 1H ) , 3.88 ( s , 3H ) , 3.84 ( s , 3H ) , 2.70 - 2.62 ( m , 1H ) , 1.87 - 1.17 ( m , 8H ) ; ES1 MS m / z 303 [ C17H22N2O3 + H1 + - . Step 2 : Synthesis of Methy1 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy - 1ate. [ 0241 ] . o ocH3 N HE> E. [ 0242 ] Fo11oWing the procedure out1ined for step 2 in Examp1e 1 , methy1 3 - ( bicyc1o [ 2.2.1 ] heptane - 2 - carboximidamido ) - 4 - methoxybenzoate ( 1 1 g , 37 mmo1 ) Was reacted With NaOC1 ( 33 mL , 10 - 13% , 44 mmo1 ) and chromatographed ( hexanes / ethy1 acetate ) to afford product ( 3.9 g , 36% ) as a foam : 1H NMR ( 300 MHz , DMSO - d6 ) de1ta 12.05 ( s , 1H , tautomer 1 ) , 11.97 ( s , 1H , tautomer 2 ) , 7.73 ( dd , 1H , J : 1.2 , 8.7 Hz ) , 6.78 ( dd , 1H , J : 2.4 , 8.7 Hz ) , 4.00 ( s , 3H , tautomer 1 ) , . ocH3. 3.98 ( s , 3H , tautomer 2 ) , 3.90 ( s , 3H , tautomer 1 ) , 3.89 ( s , 3H , tautomer 2 ) , 3.47 - 3.41 ( m , 1H , tautomer 1 ) , 3.11 - 3.06 ( m , 11 - 1 , tautomer 2 ) , 2.70 - 2.66 ( m , 11 - 1 , tautomer1 ) , 2.38 - 2.18 ( m , 2H ) , 2.08 - 2.00 ( m , 1H , tautomer 1 ) , 1.91 - 1.8O ( m , 1H , tautomer 2 ) , 1.68 - 1.24 ( m , 5H ) , 1.11 - 0.98 ( m , 1H ) ; ES1 MS m / z 301 [ C17H2ON2O3 + H ] + . US 2011 / 0263566 A1. Step 3 : Synthesis of 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic Acid. [ 0243 ] . O OH N HD 8. [ 0244 ] Fo11oWing the procedure out1ined for step 3 in Examp1e 1 , methy1 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ate ( 3.9 g , 13 mmo1 ) Was reacted With sodium hydroxide ( 30 mL , 3 M ) to afford crude product ( 3.6 g ) as a White so1id : ES1 MS m / z 287 [ Cl6Hl8N2O3 + H ] + . OH. Examp1e 64. tert - Buty1 3 - { [ 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxamido ] methy1 } piperidine - 1 - carboxy1ate. [ 0245 ] . oCH3. [ 0246 ] Fo11oWing Genera1 Procedure D 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy - 11c acid ( 125 mg , 0.43 mmo1 ) Was reacted With tert - buty1 3 - ( aminomethy1 ) piperidine - 1 - carboxy1ate ( 138 mg , 0.65 mmo1 ) to afford the desire product ( 338 mg , crude ) as an oi1 : ES1 MS m / z 483 [ C27H38N4O4 + H ] + . Examp1e 65. tert - Buty1 3 - ( ( 2 - ( bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) methy1 ) adamantane - 1 - carboxy1ate. [ 0247 ] . ocH3. Oct. 27 , 2011. [ 0248 ] Fo11oWing Genera1 Procedure D 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxy - 1ic acid ( 125 mg , 0.43 mmo1 ) Was reacted With tert - buty1 3 - aminoadamantanecarboxy1ate ( 176 mg , 0.65 mmo1 ) to afford the desire product ( 145 mg crude ) as an oi1 : ES1 MS m / z 535 [ C31H42N4O4 + H ] + . Examp1e 66. ( 3 S ) - tert - Buty1 3 - ( 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate. Boc Q. 0 NH. N w H. ocH3. [ 0249 ] . [ 0250 ] Fo11oWing Genera1 Procedure D 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxy - 1ic acid ( 150 mg , 0.54 mmo1 ) Was reacted With ( S ) - tert - buty1 3 - aminopiperidine - 1 - carboxy1ate ( 160 mg , 0.81 mmo1 ) to afford the desire product ( 237 mg crude ) as an oi1 : ES1 MS m / z 467 [ C26H36N4O4 + H ] + . Examp1e 67. tert - Buty1 ( cis ) - 4 - ( ( 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) methy1 ) cyc1ohexy1carbamate. [ 0251 ] . ooH3. [ 0252 ] Fo11oWing Genera1 Procedure D 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxy - 1ic acid ( 90 mg , 0.31 mmo1 ) Was reacted With tert - buty1 ( 1s , 4s ) - 4 - ( aminomethy1 ) cyc1ohexy1carbamate ( 71 mg , 0.31. US 2011 / 0263566 A1. mmo1 ) to afford the desire product ( 237 mg crude ) as an oi1 : ES1 MS m / z 497 [ C28H4ON4O4 + H ] + . Examp1e 68. tert - Buty1 3 - ( ( 2 - thiophene - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) methy1 ) adamantane - 1 - carboxy1ate. [ 0253 ] . OCH3. [ 0254 ] Fo11oWing Genera1 Procedure B , 7 - methoxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxy1ic acid ( 0.15 g , 0.55 mmo1 ) Was reacted With tert - buty1 3 - aminoadamantanecarboxy1ate ( 0.22 g , 0.82 mmo1 ) to afford the desired product ( 118 mg crude ) as a White so1id : ES1 MS m / z 523 [ C28H34N4O4S + H ] + . Examp1e 69. tert - Buty1 3 - ( 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate. [ 0255 ] . oCH3. [ 0256 ] Fo11oWing Genera1 Procedure B , 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxy - 1ic acid ( 150 mg , 0.55 mmo1 ) Was reacted With tert - buty1. Oct. 27 , 2011. 3 - aminopiperidine - 1 - carboxy1ate ( 0.22 g , 1.1 mmo1 ) to afford the desired product ( 219 mg crude ) as a foam : ES1 MS m / z 469 [ C26H36N4O4 + H ] + . Examp1e 70. tert - Buty1 3 - ( 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) cyc1o - hexy1carbamate. [ 0257 ] . OCH3. [ 0258 ] Fo11oWing Genera1 Procedure B , 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - methoxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxy - 1ic acid ( 150 mg , 0.55 mmo1 ) Was reacted With tert - buty1 3 - aminocyc1ohexy1carbamate ( 0.24 g , 1.1 mmo1 ) to afford the desired product ( 126 mg crude ) as a g1ass : ES1 MS m / z 483 [ C27H38N4O4 + H ] + . Examp1es 71. Kinase Assay. [ 0259 ] PBK actiVity Was determined in the presence or absence of compounds using ﬁuorescein isothiocyanate - 1a - be1ed ( F1TC - 1abe1ed ) histone H3 peptide as a substrate. The extent of F1TC - 1abe1ed histone 113 peptide phosphory1ation Was measured by immobi1ized meta1 ion afﬁnity - based ﬁuorescence po1arization ( 1MAP ) techno1ogy ( Sportsman J R , et a1. , Assay Drug DeV. Techno1. 2 : 205 - 14 , 2004 ) using 1MAP FP ProgressiVe Binding System ( Mo1ecu1ar DeVices Corporation ) . Test compounds Were disso1Ved in DMSO at 12.5 mM and then seria11y di1uted as the DMSO concentration in the assays to be 1%. The seria11y di1uted compounds , 0.8 ng / micro - L PBK ( Carna Biosciences ) and 100 nM F1TC - 1abe1ed histone H3 peptide Were reacted in a reaction buffer ( 20 mM HEPES , 0.01% TWeen - 20 , 0.3 mM MgC12 , 2 mM dithiothreito1 , 50 micro - M ATP , pH 7.4 ) at room temperature for 1 hour. The reaction Was stopped by the addition of three fo1d assay Vo1ume of progressiVe binding so1ution. Fo11oWing 0.5 hour incubation at room temperature , ﬁuorescence po1arization Was measured by Wa11ac EnVision 2103 mu1ti1abe1 reader ( PerkinE1mer ) . 1C50 Va1ues Were ca1cu1ated by non - 1inear four parameter ﬁt using SigmaP1ot , Version 10.0 ( Systat SoftWare , 1nc. ) . 1C50 Va1ues of the typica1 compounds of the present inVention are shoWn in fo11oWing tab1e 2 : . . . TABLE 2 1C50 ( microM ) Examp1e No. Compound ( kinase assay ) 38 ( S ) - 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - 0.086. benzo [ d ] imidazo1e - 4 - carboxamide. US 2011 / 0263566 A1. 38. TABLE 2 - continued. . Examp1e No. Compound. 1C50 ( microM ) ( kinase assay ) . . 35. 39. 9. 16. 17. 11. 47. 15. 45. 7. 46. 44. 19. 43. 12. 13. 42. 40. 10. 5. 18. 36. 37. 41. 6. 14. 20. 21. 8. 48. 49. 50. 51. 52. 53. 54. 7 - Hydroxy - N - ( pip eridin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. 7 - Hydroxy - N - ( pip eridin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide ( S ) - 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. ( S ) - 2 - Cyc1openty1 - 4 - hydroxy - N - ( pip eridin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. ( S ) - 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide 2 - cyc1opropy1 - 4 - hydroxy - N - ( p iperidin - 3 - y1 ) - 1 H - benzo [ d ] imidazole - 7 - carboxamide N - ( 4 - Aminocyc1ohexy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. 7 - Hydroxy - N - ( pip eridin - 2 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazole - 7 - carboxamide. 7 - Hydroxy - N - ( pyrro1idin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 7 - Hydroxy - N - ( pyrro1idin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide 4 - hydroxy - 2 - pheny1 - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazole - 7 - carboxamide N - ( Azetidin - 3 - y1methy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazole - 4 - carboxamide 2 - cyc1opropy1 - 4 - hydroxy - N - ( pyrro1idin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide N - ( azetidin - 3 - y1methy1 ) - 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. 7 - Hydroxy - N - ( pip eridin - 4 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazole - 4 - carboxamide. 7 - Hydroxy - N - ( pip eridin - 4 - y1 ) —2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - yl ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - y1methyl ) - 1H - benzo [ d ] imidazole - 7 - carboxamide 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazole - 7 - carboxamide. 7 - Hydroxy - N - [ 2 - ( pip erazin - 1 - y1 ) ethy1 ] - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide ( R ) - 7 - Hydroxy - N - ( piperidin - 3 - yl ) - 2 - ( thiophen - 2 - yl ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 7 - Hydroxy - N - ( 1 - methy1pip eridin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1 H - benzo [ d ] imidazole - 4 - carboxamide 2 - Cyc1opropy1 - 4 - hydroxy - N - ( p iperidin - 3 - y1 - methy1 ) - 1 H - benzo [ d ] imidazo1e - 7 - carboxamide 2 - cyc1openty1 - 4 - hydr0xy - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide 7 - Hydroxy - N - ( 4 - hydroxycyc1ohexy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. ( 7 - hydroxy - 2 - [ thiophen - 2 - y1 ] - 1H - benzo [ d ] imidazo1 - 4 - . y1 ) ( pip erazin - 1 - y1 ) methanone 2 - cyc1opropy1 - 4 - hydroxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide. 2 - ( Bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( p iperidin - 3 - y1methy1 ) - . 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 2 - ( Bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( p iperidin - 3 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. ( S ) - tert - Buty1. 3 - ( 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1 H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate ( S ) - 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( ( S ) - piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxa1nide 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( adamantane - 3 - y1amino ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 2 - ( Thiophene - 2 - y1 ) - 7 - hydroxy - N - ( adamantate - 3 - y1amino ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. 0.18. 0.2. 0.2. 0.27. 0.3. 0.41. 0.52. 0.59. 0.62. 0.62. 0.63. 0.73. 0.91. 0.97. 1.3. 1.6. 1.7. 1.8. 2.6. 2.9. 2.9. 3.2. 4.5. 6.2. 10. 17. 18. 26. 1.1. 0.85. 100. 0.77. 0.45. 0.5. 0.19. Oct. 27 , 2011. US 2011 / 0263566 A1. 39. TABLE 2 - continued. Oct. 27 , 2011. . Examp1e No. Compound. 1C50 ( microM ) ( kinase assay ) . . 55 N - ( 3 - Aminocyc1ohexy1 ) - 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - 0.57 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 5 6 N - { [ ( cis ) - 4 - Aminocyc1ohexy1 ] methy1 } - 2 - ( bicyc1o [ 2.2.1 ] heptan - 2.2 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 57 ( S ) - 7 - hydroxy - 2 - ( 5 - ( piperazin - 1 - y1 ) thiophen - 2 - y1 ) - N - ( piperidin - 3 .2 3 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. 5 8 ( R ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 0.69 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 59 ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 1H - 0.5 benzo [ d ] imidazo1e - 4 - carboxamide. 60 ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 0.55. 1H - benzo [ d ] imidazo1e - 4 - carboxamide. . Examp1es 72 Western B1ot Ana1ysis. [ 0260 ] To eVa1uate the expression status of PBK in seVera1 ce11 1ines , Western b1ot ana1ysis Was performed using crude ce11 1ysate co11ected from those ce11s. Anti - PBK antibody ( c1one 31 , BD Biosciences ) Was used to Visua1ize the expression. Breast cancer ce11 1ines , T47D and BT - 549 expressed PBK signiﬁcant1y a1though B1adder cancer ce11 1ine and HT - 1197 shoWed no expression of PBK. Examp1es 73 Ce11 - Based As say. [ 0261 ] ActiVe candidate inhibitors against PBK Were eVa1uated for their target - speciﬁc cytotoxicity using T47D , . BT - 549 , and HT - 1 197 ce11s Was used for negatiVe contro1. 100 micro - L of ce11 suspension Was seeded onto 96 - We11microtiter p1ate ( VieWP1ate - 96FTC , PerkinE1mer ) . The initia1 ce11 concentration of T47D , BT - 549 and HT - 1197 Were 3 , 000 ce11s / We11 , 2 , 000 ce11s / We11 and 2 , 500 ce11s / We11 , respectiVe1y. Ce11u1ar grthh Was determined using Ce11 Counting Kit - 8 ( DOJ1NDO ) at 72 hours after the exposure of the candidate inhibitors. 1C50 Was used as an indicator of the anti - pro1iferatiVe actiVity of the inhibitors , and ca1cu1ated by seria1 di1ution method ( 0 , 1.5625 , 3.125 , 6.25 , 12.5 , 25 , 50 , and 100 micro - M ) . Accurate 1C50 Va1ues Were ca1cu1ated as described preVious1y. [ 0262 ] 1C50 Va1ues of the typica1 compounds of the present inVention are shoWn in fo11oWing tab1e 3 : . . . TABLE 3 1C5 0 1C50 1C5 0 ( microM ) ( microM ) ( microM ) Examp1e No. Compound ( BT549 ) ( T47D ) ( HT1197 ) 16 ( S ) - 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 037 2.6 19 1H - benzo [ d ] imidazo1e - 7 - carb oxamide 3 8 ( S ) - 7 - Hydroxy - N - ( piperidin - 3—y1 ) - 2 - ( thiophen - 2 - 0.46 0.3 6 33 yl ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide 9 ( S ) - 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 0.73 1.5 7.1 1 H - benzo [ d ] imidazo1e - 7 - carboxamide 3 5 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 0.77 0.81 49 1H - benzo [ d ] imidazo1e - 4 - carb oxamide 1 1 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - 1.6 3.2 44 benzo [ d ] imidazo1e - 7 - carboxamide 47 N - ( 4 - Aminocyc1ohexy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - 5 .3 6.2 5 8 y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide 41 7 - Hydroxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 2 - ( thiophen - 8.1 9.8 24 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide 7 2 - Cyc1opropy1 - 4 - 11ydroxy - N - ( piperidin - 2 - y1methy1 ) - 9.5 1 1 >100 1 H - benzo [ d ] imidazo1e - 7 - carboxa1nide 3 9 7 - Hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 15 8.6 >100 2 - y1 ) - 1 H - benz0 [ d ] imidazo1e - 4 - carboxamide 44 7 - Hydroxy - N - ( pyrro1idin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 15 20 >100 1H - benzo [ d ] imidazo1e - 4 - carb oxamide 3 7 ( R ) - 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - 20 1 1 >100 y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide 10 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - y1 ) - 1H - 20 19 >100 benzo [ d ] imidazo1e - 7 - carboxamide 15 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 25 21 >100 1 H - benzo [ d ] imidazo1e - 7 - carboxa1nide 45 7 - Hydroxy - N - ( piperidin - 2 - y1methy1 ) - 2 - ( thiophen - 29 7.8 >100 2 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide 6 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 - methy1 ) - 3 0 55 >100. 1H - benzo [ d ] imidazo1e - 7 - carboxamide. US 2011 / 0263566 A1. Oct. 27 , 2011. . . 40 TABLE 3 - continued 1C50 1C5 0 1C50 ( microM ) ( microM ) ( microM ) Examp1e No. Compound ( BT549 ) ( T47D ) ( HT1197 ) . 18 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 2 - y1methy1 ) - 1H - 3 1 15 98 benzo [ d ] imidazo1e - 7 - carboxamide. 12 2 - cyc1opropy1 - 4 - hydroxy - N - ( pyrro1idin - 3 - y1 ) - 1H - 47 58 >100 benzo [ d ] imidazo1e - 7 - carboxamide. 40 7 - Hydroxy - N - ( piperidin - 4 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 73 13 >100 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 48 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - 20 49 100 ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 49 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - piperidin - 0.65 4.1 14 ( 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 51 ( S ) - 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - N - 0.18 0.14 5 .7 ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 52 2 - ( Bicyclo [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( ( S ) - 0.43 2.3 19 piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 53 2 - ( Bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - 4.6 5 .2 24 ( adamantane - 3 - y1amino ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 54 2 - ( Thiophene - 2 - y1 ) - 7 - hydroxy - N - ( adamantate - 3 - 3.3 1 .6 10 y1amino ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 55 N - ( 3 - Aminocyc1ohexy1 ) - 2 - ( bicyc1o [ 2.2.1 ] heptan - 2.9 9.1 74 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 5 6 N - { [ ( cis ) - 4 - Aminocyc1ohexy1 ] methy1 } - 2 - ( bicyc1o 10 30 61 [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxatnide. 57 ( S ) - 7 - hydroxy - 2 - ( 5 - ( piperazin - 1 - y1 ) thiophen - 2 - y1 ) - 1.1 1.1 33 N - ( p iperidin - 3 - y1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. 5 8 ( R ) - 7 - hydroxy - N - ( piperidin - 3 - ylmethy1 ) - 2 - ( thio - 13 24 21 phen - 2 - y1methy1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide. 59 ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - 2.9 11 76 y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 60 ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thio - 49 42 33. phen - 2 - y1methy1 ) - 1 H - benzo [ d ] imidazole - 4 - carboxamide. . “>100” in the table means oVer 100 microM. [ 0263 ] . 1NDUSTR1AL APPL1CAB1L1TY. The present inVention proVides a noVe1 7 - Hydroxy - . benzoimidazo1e - 4 - y1 - methanone deriVatiVe compound haVing PBK inhibitory effect. The compounds of the present inVention may be used for pharmaceutica1 composition for inhibiting PBK. Such pharmaceutica1 compositions are suit - ab1e for treating or preVenting cancer. 1. A compound represented by fo1mu1a ( 1 ) , or a sa1t , hydrate , so1Vate , or isomer thereof : . Wherein. o L— ( CH , ) , —M. . E\>7X. OH. X is pheny1 , thiophen - 2 - y1 , furan - 2 - y1 , cyc1opropy1 , cyc1o - penty1 , pheny1 - C1 - C6 a1ky1 , thiophen - 2 - y1 - C 1 - C6 a1ky1 , furan - 2 - y1 - C1 - C6 a1ky1 , cyc1opropy1 - C1 - C6 a1ky1 , cyc1o - . penty1 - Cl - C6 a1ky1 , or bicyc1o [ 2.2.1 ] heptan - 2 - y1 , Wherein each group is optiona11y substituted by 1 - 3 substituent ( s ) that are each independent1y se1ected from a mm A ; . L is —NH— , or a sing1e bond ; . M is C3 - C 10 cyc1oa1ky1 , or a 3 - 8 membered saturated heterocyc1ic group , each optiona11y substituted by 1 - 3 substituent ( s ) that are each independent1y se1ected from the 8r0up A ; . Wherein the group A is se1ected from the group consisting of hydroxy1 , oxo , nitro , cyano , amino , C , - C6 a1ky - 1amino , C3 - C 10 cyc1oa1ky1amino , amide , ha1ogen , su1famoy1 , triﬁuoromethy1 , p - to1uenesu1fony1amino , Cl - C6 a1ky1 , C3 - ClO cyc1oa1ky1 , C1 - C6 a1koxy , Cl - C6 a1koxycarbony1 , C1 - C6 a1ky1carbony1amino , C1 - C6 a1ky1su1fo - ny1 , C1 - C6 a1ky1su1fony1amino , C1 - C6 alkeny1 , C1 - C6 a1kyny1 , phosphory1 , carbony1 , carboxy1 , and a 3 - 8 membered saturated heterocyc1ic group ; and. a is an integer from 0 to 5. 2. 1he compound of claim 1 , Wherein M is piperidin - 4 - y1 , piperidin - 3 - y1 , piperidin - 2 - y1 , piperazin - 1 - y1 , pyrro1idin - 3 - y1 , azetidin - 3 - y1 , cyc1ohexy1 , or adamantan - 3 - y1 , Which are each optiona11y substituted by 1 or 2 substituent ( s ) that are each independent1y se1ected from the group A. 3. The compound of c1aim 1 , Wherein X is thiophen - 2 - y1. US 2011 / 0263566 A1. 4. The compound of c1aim 1 , Wherein X is pheny1. 5. The compound of c1aim 1 , Wherein X is cyc1opropy1. 6. The compound of c1aim 1 , Wherein X is cyc1openty1. 7. The compound of c1aim 1 , Wherein X is bicyc1e [ 2.2.1 ] heptan - 2 - y1. 8. The compound of c1aim 1 , Wherein X is 5 - bromothiophen - 2 - y1. 9. The compound of c1aim 1 , Wherein X is 5 - ( piperazin - 1 - y1 ) thiophen - 2 - y1. 10. The compound of c1aim 1 , Wherein X is thiophen - 2 - y1methy1. 11. The compound of c1aim 1 , se1ected from the group consisting of : 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 - methy1 ) - 1 H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1opropy1 - 4 - hydroxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , ( S ) - 2 - cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 4 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1opropy1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1opropy1 - 4 - hydroxy - N - ( pyrro1idin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , N - ( azetidin - 3 - y1methy1 ) - 2 - cyc1opropy1 - 4 - hydroxy - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , ( S ) - 2 - Cyc1openty1 - 4 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , ( S ) - 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 4 - Hydroxy - 2 - pheny1 - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 7 - carboxamide , 7 - Hydroxy - N - ( 4 - hydroxycyc1ohexy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , ( 7 - hydroxy - 2 - [ thiophen - 2 - y1 ] - 1 H - benzo [ d ] imidazo1 - 4 - y1 ) ( piperazin - 1 - y1 ) methanone , 7 - Hydroxy - N - ( pipe1idin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , 7 - Hydroxy - N - [ 2 - ( piperazin - 1 - y1 ) ethy1 ] - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , ( R ) - 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , ( S ) - 7 - Hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , 7 - Hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , 7 - Hydroxy - N - ( piperidin - 4 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , 7 - Hydroxy - N - ( 1 - methy1piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , 7 - Hydroxy - N - ( piperidin - 4 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . Oct. 27 , 2011. N - ( Azetidin - 3 - y1methy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 7 - Hydroxy - N - ( py1ro1idin - 3 - y1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 7 - Hydroxy - N - ( piperidin - 2 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 7 - Hydroxy - N - ( py1ro1idin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . N - ( 4 - Aminocyc1ohexy1 ) - 7 - hydroxy - 2 - ( thiophen - 2 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 2 - ( Bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 2 - ( Bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . ( S ) - tert - Buty1 3 - ( 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamido ) piperidine - 1 - carboxy1ate , . ( S ) - 2 - ( 5 - bromothiophen - 2 - y1 ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 2 - ( Bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( ( S ) - piperi - din - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 2 ( Bicyc1o [ 2 .2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - N - ( 3 - aminoadamantane - 1 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . 2 - ( Thiophene - 2 - y1 ) - 7 - hydroxy - N - ( 3 - aminoadamantane - 1 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide ) , . N - ( 3 - Aminocyc1ohexy1 ) - 2 - ( bicyc1o [ 2.2.1 ] heptan - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . N - { [ ( cis ) - 4 - Aminocyc1ohexy1 ] methy1 } - 2 - ( bicyc1o [ 2.2. 1 ] heptan - 2 - y1 ) - 7 - hydroxy - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . ( S ) - 7 - hydroxy - 2 - ( 5 - ( piperazin - 1 - y1 ) thiophen - 2 - y1 ) - N - ( piperidin - 3 - y1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . ( R ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide , . ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1 ) - 2 - ( thiophen - 2 - y1m - ethy1 ) - 1 H - benzo [ d ] imidazo1e - 4 - carboxamide , and. ( S ) - 7 - hydroxy - N - ( piperidin - 3 - y1methy1 ) - 2 - ( thiophen - 2 - y1methy1 ) - 1H - benzo [ d ] imidazo1e - 4 - carboxamide. 12. A method for preparing a compound of c1aim 1 Which. comprises the steps of : . contacting a carboxya1ky1 substituted ani1ine deriVatiVe With a nitri1e in the presence of an acid to form an intermediate amidine ; . cyc1izing the intermediate amidine to form a benzimida - zo1e deriVatiVe haVing a carboxya1ky1 ; . saponifying the carboxya1ky1 of the benzimidazo1e deriVatiVe to form a carboxy1ic acid ; and. contacting the carboxy1ic acid of the benzimidazo1e deriVatiVe With an amine deriVatiVe , to obtain the compound of c1aim 1. 13. A pharmaceutica1 composition comprising at 1east one compound of c1aim 1 and a pharmaceutica11y acceptab1e car - r1er. 14. The pharmaceutica1 composition of c1aim 13 Which is aVai1ab1e for preVenting or treating PBK dependent diseases. 15. The pharmaceutica1 composition of c1aim 14 , Wherein the PBK dependent disease is cancer. 16. A PBK inhibitor comprising at 1east one compound of c1aim 1. 17. A method for treating a PBK dependent disease in a subject , comprising administering to said subject an effectiVe amount of a compound of c1aim 1. 18. ( cance1ed ) . 44 44 44 44 44